2011 Annual Report

LLS-funded researchers accelerating cures

Sixty years ago, the de Villiers family began funding research to find the cure for blood cancers, including the leukemia that John E. Walter killed their beloved son. Their vision became The Leukemia & Lymphoma Society (LLS). Forty years ago, President Nixon President and CEO signed the National Cancer Act, elevating curing cancer to a national priority. Since then, we have gone from talking about cancer, to talking about cancers — from cure to cures. With microscopes, researchers saw different types of leukemia, lymphoma, and myeloma. Then, with amazing technologies that took decades to develop, researchers found molecular abnormalities that can cause cancers, and thereby found more subtypes, and even more cancers. With this information, we’ve gone from killing every dividing cell, including healthy cells, to putting cancer cells in the bullseye. State-of-the-art molecular tests can find specific abnormalities and new molecularly “targeted” therapies can selectively kill cancer cells. LLS-funded researchers have led the way with advances like Rituxan®, Gleevec® and Velcade®.

LLS is still funding academic scientists to make the discoveries that can provide every blood cancer patient a safe Scott Carroll and effective therapy. In 2011 alone, LLS funded hundreds of scientists around the world. In this report, you will read five Chair of their stories, showing we are closer to cures than ever. As the researchers say, it’s just a matter of time and money, and LLS is providing the dollars that can shorten the days. For some blood cancers, the knowledge base is so great that LLS can now drive lab advances to clinical trials, even faster, through strategic alliances. One of these stories is here too. LLS is partnering with a biotechnology company to accomplish the clinical trial that may lead to approval by the Food and Drug Administration of a new drug for patients with myelodysplastic syndromes. Importantly, scientists have begun to find similarities between cancers too. Drugs that were first approved to help patients with a specific subtype of blood cancer, are showing promise or are already approved as treatments for patients with other blood cancers and even solid tumors. This is a critical time. We are on the threshold of amazing new breakthroughs. We present to you, our 2011 top stories.

1 Beating pediatric cancers “Using those same tests, we can develop is anything but kids’ stuff better anti-leukemia drugs that will target the abnormalities that make some children’s Step by step, from the lab to ALL more aggressive.” clinical trials to saving lives Susan Rheingold, MD, is conducting New therapies that specifically inhibit clinical and translational research cancer-promoting molecules can be safer focusing on acute lymphocytic and more effective than today’s treatments. leukemia (ALL) in children “Ideally these new, designer drugs will and adolescents. “Research has lead to increased cure rates for these already led to improvements young patients.” in outcomes for young ALL patients — 80% of pediatric Of mice and children patients are cured with A molecule called mTOR has been frontline therapy,” says implicated in multiple cancers. “My Rheingold. colleague, Stephen Grupp, MD, PhD, and his laboratory showed a drug that Rheingold adds however inhibits mTOR can kill ALL cells that some young patients and increase survival in leukemic mice. still succumb to their With LLS funding, we translated this cancers, or pay for their exciting laboratory finding into a Phase I cures lifelong owing to the clinical trial of an oral mTOR inhibitor toxicities of standard treatments. (called sirolimus) for children and In the past several years, adolescents with relapsed acute leukemias Rheingold’s ability to predict and lymphomas,” says Rheingold. which ALL patients are at high risk Rheingold goes on to explain, “We of relapse has improved, based performed laboratory studies in ‘real time’ upon cutting-edge molecular with leukemia cells collected from the tests. Rheingold says, children who enrolled in the clinical trial. This is giving us important clues as to which combinations of drugs might work even better than mTOR inhibitors alone.”

2 Trials, trials and more trials One Molecule: Up close Rheingold is currently leading a Phase II and personal trial of sirolimus combined with oral Insights could be the key methotrexate for young patients with to saving lives relapsed/refractory ALL or non-Hodgkin Katherine Borden, PhD, is working to lymphoma. And more good news: develop new therapies that target specific a successful trial led to the Food and molecular abnormalities in cancer cells. Drug Administration (FDA) approval She is using multiple high-tech approaches of another mTOR inhibitor, temsirolimus. to understand one particular molecule To try to get even better outcomes, a new in great detail. trial combining this drug with a standard ALL chemotherapy will be done through “We discovered that too much of a factor the Children’s Oncology Group (COG). called eIF4E can cause cells to become And another early-phase clinical trial will cancerous and that acute myeloid leukemia combine temsirolimus with a standard (AML) cells typically have a lot of it, chemotherapy for pediatric patients with especially M4 and M5 AML cases. relapsed cancers. This molecule normally controls when and how much RNA is turned into The LLS impact proteins,” notes Borden. Rheingold explains, “I care for patients “But we think this molecule can be a key every week. Without the money from to controlling at least some types of AML.” LLS to do the research, write and run clinical trials, this work would not get Something old, something new, done. The impact LLS has on my patients something recycled and families as far as emotional support, RNA is the critical intermediary step education conferences and materials, between genes and the functional proteins family connections and outreach programs they encode, and abnormalities that change is invaluable. LLS provides it all.” the levels of specific RNAs have long been associated with cancer formation. Other LLS-funded investigators have shown that many blood cancers harbor anomalies in networks of molecules that normally control specific RNA production, including the mTOR molecule. New designer drugs that inhibit these molecules are being tested as anti-cancer drugs. Borden clarifies, “We are instead focused on eIF4E and on re-purposing an old anti-viral drug called ribavirin that blocks viral replication by blocking eIF4E activity.

3 eIF4E has never been targeted in a cancer A bullseye for new therapy before, but we showed it targeted treatments can stop the growth of leukemia cells Zeroing in on the Achille’s heel in the laboratory.” in multiple cancers With her clinical colleagues, Borden just Robert Orlowski, MD, PhD, is focused completed a clinical trial of ribavirin for on helping patients with multiple myeloma, patients with M4 and M5 types of AML. non-Hodgkin and Hodgkin lymphomas. Ribavirin was well-tolerated, consistent He uses laboratory models to validate with decades of its safe use to control new molecular targets and test new viral infections. And, there were substantial targeted therapies. “Our laboratory studies clinical benefits, including remissions. led to a more detailed understanding of myeloma and lymphoma biology, Borden says “I am currently leading allowing us to make clinical advances a Canada-wide clinical trial, supported with new molecularly targeted therapies,” by LLS, to test ribavirin in combination says Orlowski. “We helped show that with low dose cytarabine for AML patients. bortezomib, now known as Velcade®, There’s hope that the combination will be potently inhibits the proteasome and can even more effective than either drug alone.” safely and effectively kill myeloma cells.” She goes on, “It’s important to note that roughly 30% of all human cancers are The proteasome is an enzyme complex characterized by eIF4E abnormalities, that degrades damaged or otherwise so there are implications beyond leukemia defective proteins. Cancer cells in particular for our work.” depend on proteasomes because they are so full of abnormal proteins; inhibiting Partnering with LLS the proteasome can kill cancer cells while Three back-to-back Translational sparing normal cells. Research grants from LLS and support from the Therapy Acceleration Program Orlowski and colleagues went on to show took Borden from early laboratory that Velcade works especially well when ® clues to clinical trials. Explains Borden, combined with another drug called Doxil , “The advice I’ve received from the LLS leading to the FDA approval of this Research Department staff and Medical combination for myeloma patients. And & Scientific Committee members has it looks like proteasome inhibitors will been instrumental in the design and work against a wide range of cancers. interpretation of my clinical trials.” Velcade is also FDA approved for certain lymphoma patients and is showing promise “Without LLS support, none of this in clinical trials for patients with other work would have been possible at all. blood cancers as well as solid tumors. I am deeply grateful to LLS and its many supporters,” says Borden.

4 On the way to helping even more patients Orlowski notes, “My lab is now working on even more effective proteasome inhibitors, as well as drugs that target other myeloma- and lymphoma-associated molecules, including a lymphoid growth factor known as IL-6.” Orlowski’s laboratory results have advanced carfilzomib, which the FDA Closing in on Vaccines recently put on the “Fast Track” for full to Prevent Relapse approval. And, he and his colleagues are testing the IL-6 blocking antibody Helping immune cells drug, siltuximab, for patients with newly block cancer diagnosed, symptomatic multiple Larry Kwak, MD, PhD, is on a mission. myeloma.They are using the new drug He’s learning how to help a patient’s to improve a common drug combination own immune system deal cancer a deadly that just doesn’t work well enough blow. “Blood cancer patients actually for many patients. have cancer in their immune systems,” explains Kwak. “And, most of today’s LLS and Orlowski chemotherapies further weaken these After first receiving funding from LLS important cells.” in 1999, Orlowski studied the experimental There’s actually a weak immune response drug now known as Velcade. Orlowski at the onset of cancer that is somehow shut points out, “Most recently, LLS funded our down. Kwak is developing vaccines that studies of carfilzomib. We showed potent can bolster these anti-cancer responses activity against multiple myeloma cells in and help blood cancer patients live longer, 2007, and now the drug is helping patients.” healthy lives. “The many supporters who help fund LLS research are the reasons that I can do Outsmarting cancer the work I do.” Kwak first worked on a cancer vaccine for patients with a B-cell cancer called follicular lymphoma. “To make the vaccine, we purified unique, ‘idiotype’ protein from each patient’s malignant B cells. In a very large clinical trial, these customized vaccines were given back to patients after they had achieved remissions with a multi-drug therapy that was standard at the time,” says Kwak.

59 The customized vaccines prevented Kwak and his team are also learning which relapses, but not for every patient. tumor-derived proteins can be successfully So, Kwak went back to work. used in vaccinations for leukemia and lymphoma patients. And, in two other In Texas, Kwak and his LLS-funded team projects, they’re testing antibodies that can are working on vaccines for leukemia, reinvigorate immune cells that have been myeloma and lymphoma patients, to be deactivated by the very cancer cells they used after or even instead of chemotherapy. should be fighting. A Phase II clinical trial “Our work tells us that vaccines will be part is already underway using one approach of the therapeutic answer to many cancers. to help follicular lymphoma patients. A vaccine has been approved for prostate cancer patients and my old colleagues LLS — steadfast for research at the National Cancer Institute (NCI) In 2007, LLS funding helped Kwak are making great progress on an anti- improve those lymphoma vaccines. melanoma vaccine.” In 2008, he received a prestigious, multi- million dollar grant from LLS, allowing “Educated” Immune Cells and what they’re teaching us Kwak and his team to work on myeloma In one of his LLS-funded projects, and leukemia vaccines as well. And this Kwak is developing a vaccine in which year, Kwak received another grant from healthy donors are immunized with purified LLS to move a promising targeted therapy myeloma proteins and then the educated forward. “We would not be making immune T cells are collected and given as much progress, or as fast, without to myeloma patients along with a stem cell LLS support,” says Kwak. transplant. A first clinical trial has just been successfully completed, with no clinical complications. To make the approach more broadly useful, Kwak says, “We are doing additional laboratory studies to learn if we can effectively immunize healthy T cells in the laboratory rather than in the donor.”

6 Cross-Country Melnick worked with LLS-funded Newly discovered epigenetic Collaboration Casts collaborators in Chicago to engineer abnormalities can cause blood a Wider Net for Success an unusual, protein-based BCL6 inhibitor. cancers too By including a piece of a viral protein, Genes can be mutated to cause cancers, New drug for lymphoma this new drug can get into the nucleus but can also be changed by the addition patients is shining light for of very small chemical groups in a process other cancer patients as well of cancer cells where it kills them from called methylation. In addition to his work Ari Melnick, MD, is learning how to target the inside out. The drug, called RI-BPI, with BCL6, Melnick is developing tests master regulator molecules, or transcription kills lymphomas growing in mice. And, that can find these epigenetic abnormalities factors, that can cause cancers when it can help kill leukemia cells that are not in specific cancer cases. He and his team hyperactivated. He’s focused on the BCL6 sensitive to standard drugs, as Melnick have shown that aberrant DNA methylation molecule in particular, a molecule which has shown with yet another LLS-supported occurs almost universally in leukemias LLS-funded colleagues in New York found researcher in San Francisco. and lymphomas, and occurs in genes that in aggressive cases of B-cell lymphoma. “That’s great news,” says Melnick. “And are not commonly mutated. “When we learned that the molecule with additional financial help from LLS, Melnick points out, “This new information must attach to certain co-factors to cause we are getting the drug ready for clinical will provide clues as to which patients lymphomas, we discovered an entirely trials with the hope of helping patients need higher doses of standard therapies, new way to kill lymphomas,” says with lymphoma and leukemia, and maybe and is also revealing potential targets Melnick. “In fact, transcription factors even more than that.” It turns out that for new therapies.” Melnick believes that such as BCL6 play a central role in many BCL6 abnormalities are found in a variety epigenomics will be just as critical as cancers, but have proven difficult to target of cancers, including breast cancer. genomics to developing optimal treatments with typical drugs.” for patients with many different cancers.

LLS — partner in progress LLS has been an avid supporter of Melnick and his work. “All the research grants that I have received from LLS have helped me develop my research program, including the grant that helped me launch my BCL6 research. In fact, without LLS, we would simply not have gotten this far so fast. And, we’re still going.”

7 Seeing huge potential LLS is now partnering with Onconova in a drug that stops to advance Estybon as a treatment cancer in its tracks for MDS patients whose cancers are not controlled by available drugs and/or Blocking progression are likely to progress to AML. LLS to acute leukemia will provide up to $10 million to support Onconova Therapeutics, Inc. is a a multicenter, randomized, Phase III biotechnology company based in Newtown, clinical trial that could lead to its approval PA and Princeton, NJ. It discovers and by the FDA. develops new drugs that target molecules involved in cellular processes that can “Because MDS remains difficult go wrong in cancer cells. Scott Megaffin to manage and options are very limited is senior vice president. for patients who have a drug-resistant disease, new treatments are urgently Currently, Onconova is conducting needed,” says Megaffin. clinical trials in the US and abroad for three candidate drugs. One of these, Accelerating Advances ® Estybon , is a drug that inhibits multiple LLS has committed substantial, multi- enzymes that many cancers especially year funding to support this collaboration need to proliferate. Early phase clinical as part of its Therapy Acceleration Program. trials have shown that Estybon can be By partnering directly with biotechnology safely used, with clinical responses companies like Onconova, LLS is working in patients with solid tumors and blood to shorten the time it takes for potentially cancers, including myelodysplastic breakthrough therapies to obtain FDA syndromes (MDS). approval, and reach the patients who need them. ESTYBON: resistance is futile LLS already knew about Estybon through Megaffin says, “We will be able to expedite its support of a research team at Stanford this important clinical trial of Estybon University, led by Beverly Mitchell, MD. due to the support we receive from LLS.” Team member Peter Greenberg, MD, led Michael B. Hoffman, Chairman of the a Phase II clinical trial that showed the drug Board of Directors of Onconova, recently can be well-tolerated and help MDS patients said in the press release describing this at high risk of progression to AML. When partnership, “We are honored that LLS these secondary AMLs evolve, they are recognizes the potential of Estybon usually undeterred by standard therapies. and is making a substantial investment Estybon also helped patients whose disease with Onconova, in what we hope had failed to respond to drugs known as is a pivotal trial.” hypomethylating agents, including Vidaza® and Dacogen®.

8 On the following pages are examples of the progress we made in 2011 towards achieving our mission to cure blood cancers and improve the quality of life of patients and their families.

Providing Information and simultaneously in Spanish and Portuguese. been rated number 1 in the nation Support at Diagnosis and More than 51,000 participants attended by oncologists in response to the 2011 Throughout Survivorship community-based LLS chapter education Kantar Health national survey question: programs. Which of the following co-pay foundations Education do you consider best regarding helping In 2011, we launched Paths to Recovery More than 16,000 primary care providers, your patients? – Stories From Two Blood Cancer hematologist/oncologists and other Survivors, an illuminating video featuring healthcare providers participated in Community Support guidance from clinical experts and survivors Strategies for Shared Care of Patients More than 3,200 school personnel, sharing their experiences. Nearly 11,600 With Hematologic Malignancies. This healthcare professionals and parents viewers gained insights on coping with online professional education activity, attended the LLS program Welcome Back: fatigue, anxiety, depression and pain. developed in partnership with Medscape Working Together to Support the Cancer Oncology, explores a multidisciplinary Over 251,000 patients, caregivers and Survivor at School. More than 13,100 approach to managing hematologic cancer. healthcare professionals attended LLS survivors attended 452 family support groups offered by LLS chapters across national telephone/web education programs, Information, Referral including new programs that were offered and Financial Support the US and Canada. A diverse group of nearly 70,000 Chapter staff and volunteers continue patients, family members and healthcare to strengthen relationships and build new To be told that you have professionals communicated with ones with community-based organizations master’s-level information specialists serving Latino/Hispanic, African-American, cancer and to undergo about treatment decisions, advances rural, and other underrepresented cancer cancer treatment is tremendously in blood cancer management, financial patients. In all, 32,833 cancer patients matters and life after a cancer diagnosis. and caregivers participated in 479 activities stressful…many people find Information specialists worked with and programs, made possible by the in retrospect only that the individuals representing many diagnoses outreach and collaborative efforts of LLS and stages from communities across chapters to underrepresented groups across experience wasn’t all bad…the the US and Canada. And a record-breaking the US and Canada. 6,100 customized clinical trial searches ‘new normal’ can in some ways In addition, we’re proud to report that were conducted using the blood-cancer be more rewarding and more 5,094 Patti Robinson Kaufmann First specific search tool Trial Check®. gratifying than the old normal Connection matches were made between Nearly $38 million was awarded through patients, their family members and trained was. But it takes a long process the LLS Co-Pay Assistance Program peer volunteers. to get to that.” to help patients with prescription drug co-pays and insurance premium obligations. Lissa Parsonnet, PhD, Paths to Recovery The LLS Co-Pay Assistance Program has 9 Research Grants Two multi-million dollar grants were also 3 In an agreement with Epizyme, LLS continues to support the development awarded through our Specialized Centers LLS will provide up to $7.5 million of breakthrough cancer therapies, of Research (SCOR) program. Frederick for pre-clinical and Phase I clinical committing substantial funding to Alt, PhD, and his SCOR team have been testing of a new targeted therapy researchers around the world. This fiscal funded by LLS since 2006. They are for patients with Mixed Lineage year, we made 83 new awards, including learning how B-cell lymphomas evolve Leukemia, including adults and 45 Career Development grants. Seventeen and which molecules can serve as targets children. The therapy inhibits of 36 new Translational Research awards for new lymphoma therapies. Anthony another epigenetics enzyme that were responsive to specific requests Green, MD, PhD, and his team also plays a central role in these leukemias. for proposals in four underdeveloped received their first SCOR award in 2006. Progress in Clinical Trials but promising areas of research, including They are developing better diagnostics LLS also continued to support progress novel strategies to target: and therapeutics for patients with myeloproliferative neoplasms. through five ongoing partnerships: 1 AML and myelodysplastic 1 Memgen reported results of their syndromes (MDS); Biotech Alliance Partnerships Phase I trial of a novel immune- 2 Non-cutaneous T-cell malignancies; LLS partners directly with biotechnology stimulating treatment, ISF35, 3 High-risk cases of myeloma; companies to more quickly develop with 56% of high-risk chronic 4 Long-term and late effects of today’s potential blood cancer therapies. This fiscal lymphocytic leukemia (CLL) cancer therapies. year, we forged three new alliances: patients achieving a complete 1 LLS will provide up to $1.7 million response. to Ascenta Therapeutics for the 2 Avila Therapeutics completed clinical development of AT-406, a Phase I study in healthy volunteers a drug that promotes cancer cell that identified an active starting dose This fiscal year, LLS made 83 new death, as a treatment for patients with for the Phase Ib study of AVL-292. awards, forged three new alliances, poor risk AML. The drug entered This oral drug inhibits a growth- a Phase I clinical trial in March 2011. promoting enzyme that is abnormally and supported progress through 2 In a partnership with Acetylon active in many cases of non-Hodgkin Pharmaceuticals, Inc., LLS will lymphomas, CLL and Waldenstrom’s five ongoing partnerships. provide up to $4.85 million for macroglobulinemia. The Phase Ib the clinical testing of ACY-1215, study was initiated in July 2011 a drug that inhibits a specialized for patients with these cancers. epigenetics enzyme. A Phase Ia clinical trial began enrolling patients with relapsed or relapsed/refractory multiple myeloma in August 2011.

10 The Voice of The Leukemia & Lymphoma Society heard in 2011

3 The University Health Network LLS Oral Chemotherapy Coverage For Patients and in Toronto opened a Phase I Leading coalition campaigns in New York their Families clinical trial of the repurposed advocates and Illinois, LLS advocates were successful LLS stormed Capitol Hill in June anti-fungal drug, ciclopirox olamine, grew to in increasing patient access to oral cancer when more than 80 high-level advocacy as a treatment for patients with treatments by requiring insurance companies delegates conducted meetings with more relapsed or refractory AML. more than to provide coverage for oral chemotherapy than 100 congressional offices. Vital issues This project originated in LLS 56,000 at a cost equal to what is charged for to blood cancer patients included: increased grant-funded results of Aaron intravenous (IV) treatment. funding for cancer research at the National Schimmer, MD, PhD, FRCPC. volunteers Institutes of Health and National Cancer This coverage is now required by 14 states 4 Celator Pharmaceuticals reported Institute; continued funding for the Centers and the District of Columbia. Forging promising results for their Phase II for Disease Control and Prevention’s Blood ahead, LLS advocates are also diligently clinical trial of CPX-351 for older Cancer Education Program; the initiation leading similar efforts in South Carolina patients with newly diagnosed AML, of the Cures Acceleration Network; and Wisconsin. with an improvement in overall and a fix to the ongoing drug shortage survival for patients with cases Cord Blood Banking issue plaguing patients with cancer of secondary AML. This drug and Donation and other chronic diseases. is a novel lipid formulation of two LLS volunteers successfully advocated The Growing Family of LLS standard anti-cancer drugs. for passage of legislation in Florida during LLS advocates grew to more than 56,000 5 Onconova Therapeutics, Inc. the 2011 legislative session that requires volunteers, an empowered voice for patients opened a large Phase III clinical trial physicians and hospitals to inform expectant and their families. Advocates now have of a new drug for adult MDS patients mothers of the importance of cord blood more choices as to where and how they’d who have relapsed and/or become banking and donation. A similar bill like to exercise those voices, including resistant to available drugs (Vidaza®, passed the Iowa State Senate this spring, participation in LLS’s Advocacy Center, Dacogen®). This trial could lead and LLS will work tirelessly to pass the bill LLS’s Call for Cures website, the LLS to FDA approval of Estybon®, in the Iowa House of Representatives Facebook page, a new advocacy-specific a drug that selectively inhibits during the 2012 legislative session. Passage Twitter feed [http://twitter.com/ multiple enzymes involved in cancer of these bills will increase umbilical cord LLSAdvocacy] and a new LLS Advocacy cell proliferation. It is also being blood resources and expand the resources Community [http://community.lls.org/ tested for patients with lymphoid available for stem cell matching and community/advocacy]. The voice of LLS cancers and various solid tumors. transplantation for the treatment of blood continues to touch more issues and cancer patients. LLS advocates continue communication points than ever before. to lead coalition efforts to pass this legislation in states around the country.

11 with nearly 250 employees participating. Team In Training Man & Woman of the Year www.teamintraining.org In addition to being a part of the TNT www.mwoy.org Corporate Team Program, UnitedHealthcare, Team In Training (TNT) continues America’s preeminent healthcare company, This spirited campaign continues to bring to be the industry leader in charity became the newest Presenting Sponsor together dynamic volunteer community endurance training programs with over of Team In Training. leaders with the single goal of raising 2,300 coaches across the United States Many TNTers who participated in signature as much money as possible in 10 weeks and Canada delivering the “best in class” events and on corporate teams did so as to benefit LLS’s mission. 690 honored training program to get our 40,000 a part of the TNT Flex team. TNT Flex was candidates participated in 62 campaigns participants across the finish line. created in order to provide great customer around the country this year — including This year LLS saw great success with service and flexibility for participants who 6 new campaigns. All candidates who its TNT Corporate Team Program growing are not be able to do the traditional TNT confirmed their participation were formally to 21 national teams. Deloitte led the way in-person program. This year TNT Flex was thanked in a full-page USA Today with recruitment and was the top national expanded to include participants interested advertisement. corporate team raising over $475,000 in cycle and hike. We continue to focus on increasing volunteer leadership through nominating Light The Night Walk committees and candidate campaign www.lightthenight.org teams. Our 2011 National Man & Woman of the Year are a testament to the power Raising over $45 million last year, our of a campaign team. Man of the Year annual Light The Night Walk continues Ian O’Malley and Woman of the Year to engage the business community, Kelley LaFontaine both formed campaign patients and their families. Walking in 200 teams. Together, their campaigns raised communities across the US and Canada, over $340,000. In fact, of the 690 250,000 Light The Night participants participating candidates, 82 raised enough fundraise to become a “Champion For funds to qualify for the top fundraising Cures” by raising $100 or more. Recruiting recognition program. business leaders to spearhead the effort as Corporate Walk Chairs and developing local volunteer leadership committees has been key to the success of Light The Night. Our 65 National Partners raised $9 million last year, with Burlington Coat Factory remaining our top corporate partner raising more than $2.5 million.

12 Parry/CGi Nigel by Photo A special thank you goes out to Olive School & Youth Program www.schoolandyouth.org Garden, who for 18 years has been supporting LLS through the Pasta This year, nearly a quarter of schools for Pennies program. During Pasta for across the country participated in School Pennies, the top fundraising classroom & Youth Programs — Pasta for Pennies, in participating schools receives presented by Olive Garden, and Pennies a celebratory, Hospitaliano pasta lunch for Patients — to teach kids about service, from a local Olive Garden restaurant. leadership, philanthropy and the power This year, Olive Garden supported over of spare change while helping in the fight 6,000 schools in their fundraising efforts! against blood cancers. Thanks to their efforts, kids participating in School Targeted Giving & Youth Programs raised a record-breaking anD Bequests $26 million to fund blood cancer research and patient services. The colorful, individual Just as researchers focus on specific targets collection boxes for students played a big to develop better blood cancer treatments, role in their fundraising success, along with some donors focus their giving to be an increase in school visits and educational more effective philanthropists. To facilitate assemblies conducted by LLS staff. targeted support for donors making gifts of $10,000 or more, LLS offers a dozen different research portfolios. Nine are focused on specific blood cancers and three address broader research themes: Another group of valued supporters — immunotherapies, stem cell transplantation members of our Legacy Circle — looked and long-term and late effects of treatments. into the future and included LLS in their wills or designated the organization Each portfolio contains a mix of projects as a partial beneficiary in their retirement across multiple, leading research plans or insurance policies. Their tax-wise institutions. By directing support to one decisions, which have no impact on their of these groupings, donors can focus their income today, can significantly improve philanthropy on a topic of concern while how blood cancer patients will be treated extending their reach and diversifying tomorrow. This year, research was supported charitable giving, just as investors might by $7.7 million in legacy giving. do using sector mutual funds. This year, 40 donors invested more than $2 million in research-specific portfolios. 13 research grants

The Marshall A. Lichtman Anthony Green, MD, PhD* Career Development Cristian Bellodi, PhD Jennifer Brown, MD, PhD Xi Chen, PhD Specialized Center University of Cambridge Program University of California, Dana-Farber Cancer Institute Harvard University of Research The Career Development Program San Francisco School of Public Health Helen Heslop, MD Patrick Brown, MD* 9 The Specialized Center of Research provides stipends to investigators Program funds multi-disciplinary Baylor College of Medicine of exceptional promise in the early Micah Benson, PhD Johns Hopkins University Yi-Bin Chen, MD stages of their careers, helping Harvard Medical School School of Medicine Massachusetts General Hospital research by teams of leading-edge Carl June, MD academic investigators that hasten them devote their careers to the discovery and development University of Pennsylvania leukemia, lymphoma and/or Avinash Bhandoola, MD, PhD Claudio Brunstein, MD Tao Cheng, MD of better treatments for leukemia, myeloma research. University of Pennsylvania University of Minnesota, Twin Cities University of Pittsburgh lymphoma and myeloma patients. Larry Kwak, MD, PhD University of Texas Anja-Katrin Bielinsky, PhD Lihua Budde, MD, PhD Uhn-Soo Cho, PhD A center is composed of at least Tahamtan Ahmadi, MD, PhD three independent research M.D. Anderson Cancer Center University of Minnesota, Twin Cities Fred Hutchinson Harvard Medical School University of Pennsylvania programs that are integrated Cancer Research Center Jonathan Licht, MD Daniel Billadeau, PhD Yoonsu Choi, PhD and supported by scientific core Colin Aitken, PhD* laboratories. Northwestern University Mayo Clinic and Foundation Dinis Calado, PhD University of Texas Johns Hopkins University School of Medicine Immune Disease Institute M.D. Anderson Cancer Center School of Medicine Jerry Adams, PhD Debabrata Biswas, PhD Scott Lowe, PhD 4 Rockefeller University George Calin, MD* Yuh Min Chook, PhD Walter & Eliza Hall Institute Arash Alizadeh, MD, PhD Cold Spring Harbor Laboratory University of Texas University of Texas of Medical Research Stanford University Dale Bixby, MD, PhD M.D. Anderson Cancer Center Southwestern Medical Center Beverly S. Mitchell, MD 5 University of Michigan Frederick Alt, PhD* Shannon Anderson, PhD Stanford University Kenneth Campellone, PhD Eric Chow, MD Immune Disease Institute University of California, Marie Bleakley, MD University of California, Berkeley Fred Hutchinson Stephen Nimer, MD San Francisco Fred Hutchinson Jon Aster, MD, PhD Cancer Research Center Memorial Sloan-Kettering Cancer Research Center Pedro Carvalho, PhD Brigham & Women’s Hospital Meztli Arguello, PhD* Cancer Center Harvard Medical School Wen-Ming Chu, MD, PhD Université de Montréal Michael Boddy, PhD Irwin Bernstein, MD Brown University Michael Thirman, MD 6 The Scripps Research Institute Lucio Castilla, PhD 10 Fred Hutchinson Cancer Scott Armstrong, MD, PhD The University of Chicago University of Massachusetts Elaine Chung, PhD Research Center Children’s Hospital Boston Catherine Bollard, MD 7 Medical School University of Pennsylvania Baylor College of Medicine John Byrd, MD 1 Laura Attardi, PhD Asher Chanan-Khan, MD Naomi Courtemanche, PhD The Ohio State University Stanford University Niccolo Bolli, MD Health Research Incorporated Yale University Dana-Farber Cancer Institute Riccardo Dalla-Favera, MD 2 Cynthia Barber, PhD Roswell Park Vincenzo D’Angiolella, MD, PhD Columbia University Brandeis University Ivan Borrello, MD Cancer Institute Division New York University Johns Hopkins University Brian Druker, MD 3 Craig Bassing, PhD Chong Chen, PhD* School of Medicine School of Medicine Howard Hughes Medical Institute The Children’s Hospital Memorial Sloan Kettering Monique Dail, PhD Oregon Health & Science University of Philadelphia Marina Bousquet, PhD 8 Cancer Center University of California, Cancer Institute Whitehead Institute Satarupa Basu, PhD Jing Chen, PhD San Francisco for Biomedical Research Carolyn Felix, MD University of Pennsylvania Emory University Matthew Davids, MD* The Children’s Hospital Troy Brady, PhD Uttiya Basu, PhD Wei-Yi Chen, PhD Dana-Farber Cancer Institute of Philadelphia University of Pennsylvania Immune Disease Institute Rockefeller University Renee de Pooter, PhD Andrea Bredemeyer, PhD University of Oxford Brigham & Women’s Hospital

1 Dr. John Byrd is funded in part 3 Dr. Brian Druker is funded in part 6 Dr. Michael Thirman is funded 7 Dr. Catherine Bollard is funded in part 9 Dr. Patrick Brown is funded in part by The Jim Jacobs Charitable by F.M. Kirby Foundation. in part by The Pamela B. Katten by Donald Porteous. by The Barker Family, in loving Foundation, Stanley and Sandra Memorial Leukemia Research memory of Christian Barker. 4 Dr. Scott Lowe is funded in part 8 Dr. Marina Bousquet is fully funded Kahan, Douglas A. and Phyllis Smith, Foundation, the Alverin M. Cornell by The Altschul Foundation – by Gertrude B. Elion Endowment 10 Dr. Lucia Castilla is funded in part Elaine Smith and Michael Thomas. Foundation, John and Jean Hughes Reichman Memorial. Fund. by The Robert H. Lyon Leukemia Foundation, Clyde Smith McGregor 2 Dr. Riccardo Dalla-Favera is funded Foundation and the Remillard 5 Dr. Beverly S. Mitchell is funded and LeAnn Pedersen Pope – in part by The Paul E. Singer Family Family Foundation. in part by the Joseph C. Sanfilippo In Memory of Joan Kowing Foundation, Joseph S. and Memorial Fund and The Harry T. McGregor, Paul and Joan Diane H. Steinberg Charitable Trust, Mangurian, Jr. Foundation, Inc. Rubschlager Foundation, and and J.T. Tai & Co. Foundation. The Bohnen Family Foundation. 14 Michael Deininger, MD, PhD Maria Sol Flaherty, PhD* Sara Hamilton, PhD Emma Josefsson, PhD Rhett Kovall, PhD Kevin Lin, PhD* Oregon Health & Science University Columbia University University of Minnesota, Twin Cities Walter & Eliza Hall Institute University of Cincinnati British Columbia Cancer Agency of Medical Research Ludovic Deriano, PhD* Elsa Flores, PhD* Yoon-Chi Han, PhD* Maxwell Krem, MD Weei-Chin Lin, MD, PhD New York University University of Texas Memorial Sloan-Kettering Axel Kallies, PhD University of Washington University of Alabama School of Medicine M.D. Anderson Cancer Center Cancer Center Walter & Eliza Hall Institute at Birmingham Mijung Kwon, PhD of Medical Research Luisa Di Stefano, PhD Jonathan Friedberg, MD Omid Harandi, PhD Dana-Farber Cancer Institute Allen Liu, PhD Massachusetts General Hospital University of Rochester University of Massachusetts Sumin Kang, PhD The Scripps Research Institute James LaBelle, MD Medical School Emory University J. Alan Diehl, PhD Maxim Frolov, PhD Dana-Farber Cancer Institute Mignon Loh, MD University of Pennsylvania University of Illinois, Chicago Jorge Henao-Mejia, MD, PhD Tarun Kapoor, PhD 11 University of California, Adam Lazorchak, PhD Yale University Rockefeller University San Francisco Chen Dong, PhD Boyi Gan, PhD Yale University University of Texas Dana-Farber Cancer Institute Erin Hertlein, PhD* Barbara Kee, PhD Sonja Lorenz, PhD Sang Eun Lee, PhD M.D. Anderson Cancer Center The Ohio State University The University of Chicago University of California, Berkeley Jason Garrison, PhD University of Texas Jarrod Dudakov, PhD Burnham Institute David Hesslein, PhD Younghoon Kee, PhD M.D. Anderson Cancer Center Shuo Ma, MD, PhD Sloan-Kettering Institute for Medical Research University of California, Dana-Farber Cancer Institute Northwestern University Anthony Letai, MD for Cancer Research San Francisco School of Medicine Ulrike Gerdemann, MD Hyungjin Kim, PhD* Dana-Farber Cancer Institute Mary Eapen, MBBS Baylor College of Medicine Jonathan Higgins, PhD* Dana-Farber Cancer Institute Sami Malek, MD* Mark Levis, MD, PhD 12 Medical College of Wisconsin Brigham & Women’s Hospital University of Michigan Nilanjan Ghosh, MD, PhD TaeSoo Kim, PhD Johns Hopkins University Anna Eiring, PhD* Johns Hopkins University Angela Hilliker, PhD Harvard Medical School School of Medicine Sebastien Malinge, PhD University of Utah School of Medicine University of Arizona Northwestern University Julianne Kitevski-LeBlanc, PhD* Erin Lew, PhD School of Medicine Michael Farrar, PhD Evisa Gjini, PhD* Andrew Holland, PhD* University of Toronto The Salk Institute University of Minnesota, Twin Cities Dana-Farber Cancer Institute Ludwig Institute for Cancer Research for Biological Studies Daniel Marston, PhD Myung Gon Ko, PhD* University of North Carolina Niklas Feldhahn, PhD Ananda Goldrath, PhD* Heedeok Hong, PhD La Jolla Institute Zachary Lewis, PhD at Chapel Hill Rockefeller University University of California, San Diego University of California, Los Angeles for Allergy and Immunology University of Oregon Peter Martin, MD 13 David Feldser, PhD Ajay Gopal, MD Jian Hu, PhD Andrew Koh, PhD* Shaoguang Li, MD, PhD Weill Medical College Massachusetts Institute University of Washington Dana-Farber Cancer Institute Stanford University University of Massachusetts of Cornell University of Technology Medical School Daniel Gough, PhD Yun Huang, PhD Holbrook Kohrt, MD* William Matsui, MD 14 Suhua Feng, PhD New York University Immune Disease Institute Stanford University Willis Li, PhD Johns Hopkins University University of California, Los Angeles School of Medicine University of Rochester Michael Hudecek, MD Minoree Kohwi, PhD School of Medicine David Ferguson, MD, PhD Daniel Graham, PhD Fred Hutchinson University of Oregon Zejuan Li, MD, PhD David Matus, PhD University of Michigan Washington University in St. Louis Cancer Research Center The University of Chicago Motonari Kondo, MD, PhD Duke University Medical Center Adolfo Ferrando, MD, PhD Allan Gurtan, PhD Enfu Hui, PhD* Duke University Medical Center Sergiy Libert, PhD Alexander Mazin, PhD Columbia University Massachusetts Institute University of California, Massachusetts Institute Marina Konopleva, MD, PhD* Drexel University Medical Center of Technology San Francisco of Technology Maria Figueroa, MD University of Texas Megan McNerney, MD, PhD* Weill Medical College Aaron Johnson, PhD M.D. Anderson Cancer Center The University of Chicago of Cornell University Harvard Medical School

11 Dr. Tarun Kapoor is funded in part 12 Dr. Mark Levis, a Rally Foundation * Newly awarded or renewed grants by The Robert H. Lyon Leukemia for Childhood Cancer Research in fiscal year 2012 Foundation. Scholar, is funded in part by The Rally Foundation for Childhood Cancer Research. 14 Dr. William Matsui, a Millennium: 13 Dr. Peter Martin is funded in part The Takeda Oncology Company by Lance Meyerowich and The Scholar, is fully funded by Millennium: Lymphomaniacs. The Takeda Oncology Company.

15 research grants (continued)

Ari Melnick, MD 15 Voytek Okreglak, PhD* Gunnar Ragnarsson, MD 20 Laurent Sabbagh, PhD Jeffrey Skaar, PhD* Hsin-yue Tsai, PhD Weill Medical College University of California, Fred Hutchinson University of Toronto New York University University of Massachusetts of Cornell University San Francisco Cancer Research Center School of Medicine Medical School Julien Sage, PhD Hanna Mikkola, MD, PhD* Kostandin Pajcini, PhD Noopur Raje, MD 21 Stanford University Jane Skok, PhD Cameron Turtle, MBBS, PhD University of California, Los Angeles University of Pennsylvania Massachusetts General Hospital New York University Fred Hutchinson Sandrine Sander, MD, PhD School of Medicine Cancer Research Center Stefanie Mortimer, PhD Qishen Pang, PhD Rajesh Ramachandran, PhD Immune Disease Institute University of California, Berkeley Cincinnati Children’s Hospital The Scripps Research Institute Catherine Smith, MD Shobha Vasudevan, PhD 25 Karsten Sauer, PhD Medical Center University of California, Massachusetts General Hospital The Scripps Research Institute Britta Mueller, PhD Dale Ramsden, PhD San Francisco Massachusetts General Hospital Dongsu Park, PhD University of North Carolina Suzanne Vercauteren, MD, PhD Aaron Schimmer, MD, PhD 22 Massachusetts General Hospital at Chapel Hill Zhou Songyang, PhD University of British Columbia University Health Network James Mulloy, PhD Baylor College of Medicine Cincinnati Children’s Hospital Jae Park, MD* Jeffrey Rathmell, PhD Roumen Voutev, PhD* Baerbel Schroefelbauer, PhD Medical Center Memorial Sloan-Kettering Duke University Medical Center Tracy Staton, PhD Columbia University University of California, San Diego Cancer Center Harvard University Andrew Mungall, PhD Pavan Reddy, MD Johannes Walter, PhD Suzanne Schubbert, PhD 23 School of Public Health British Columbia Cancer Agency Danilo Perrotti, MD, PhD 18 University of Michigan Harvard Medical School University of California, Los Angeles The Ohio State University Milan Stojanovic, PhD Markus Muschen, MD 16 Boris Reizis, PhD Demin Wang, PhD Rosalie Sears, PhD Columbia University Childrens Hospital Los Angeles John Perry, PhD Columbia University Blood Research Institute Oregon Health & Science University Stowers Institute Till Strowig, PhD* Anita Nag, PhD Ran Reshef, MD Gang (Greg) Wang, PhD for Medical Research Camile Semighini, PhD Yale University Yale University University of Pennsylvania Rockefeller University Duke University Medical Center Daniel Pollyea, MD 19 Jason Stumpff, PhD Shalin Naik, PhD Tannishtha Reya, PhD Lan Wang, PhD Stanford University Zhe Sha, PhD* University of Washington Netherlands Cancer Institute Duke University Medical Center Memorial Sloan-Kettering Harvard Medical School Christos Polytarchou, PhD Kelly Sullivan, PhD Cancer Center Shima Nakanishi, PhD Robin Ricke, PhD New England Medical Center Neil Shah, MD University of Colorado Stowers Institute Mayo Clinic and Foundation Rei Watanabe, MD, PhD* Hospitals, Inc. University of California, for Medical Research Wojciech Swat, PhD Brigham and Women’s Hospital, Inc. San Francisco Joel Pomerantz, PhD* David Rizzieri, MD Washington University in St. Louis Geeta Narlikar, PhD 17 Duke University Medical Center Mitchell Weiss, MD, PhD Johns Hopkins University Smita Shankar, PhD University of California, David Sykes, MD, PhD* The Children’s Hospital School of Medicine Giovanni Roti, MD University of California, San Francisco Massachusetts General Hospital of Philadelphia San Francisco Philippe Prochasson, PhD Dana-Farber Cancer Institute Jeffrey Nolz, PhD Yvonne Tay, PhD* John Welch, MD, PhD University of Kansas Medical Center James Rubenstein, MD, PhD Sonia Sharma, PhD University of Iowa Beth Israel Deaconess Washington University in St. Louis Immune Disease Institute Marc Raaijmakers, MD, PhD University of California, Medical Center Kristi Norris, PhD San Francisco William Wierda, MD, PhD Massachusetts General Hospital Warren Shlomchik, MD 24 Duke University Medical Center Sarah Thompson, PhD* University of Texas Yale University Senthil Kumar Radhakrishnan, Loredana Ruggeri, MD, PhD University of Manchester M.D. Anderson Cancer Center Christopher Oakes, PhD University of Perugia PhD* Robert Signer, PhD Deutsches Krebsforschungszentrum Joanna Tober, PhD* Jeremy Wilusz, PhD California Institute of Technology Davide Ruggero, PhD University of Michigan (German Cancer Research Center) University of Pennsylvania Massachusetts Institute University of California, of Technology San Francisco

15 Dr. Ari Melnick is funded in part 17 Dr. Geeta Narlikar is funded in part 20 Dr. Gunnar Ragnarsson is funded 22 Dr. Aaron Schimmer is funded in part 25 Dr. Shobha Vasudevan is funded by Lance Meyerowich and The by Walter and Beth Grant. in part by The For Julie Foundation, by The For Julie Foundation, Inc., in part by Donald Porteous. Lymphomaniacs. Inc. The Robert H. Lyon Leukemia 18 Dr. Danilo Perrotti is funded in part Foundation and The Roderick 16 Dr. Markus Muschen is funded by Mark and Christine Kraemer, 21 Dr. Noopur Raje, a Millennium: Seward, Flossie Radcliffe & Helen in part by the California Community and Charles and Lynda Kraemer. The Takeda Oncology Company M. Galloway Foundation. Foundation and an anonymous Scholar, is fully funded by Millennium: 19 Dr. Daniel Pollyea is fully funded donor. The Takeda Oncology Company. 23 Dr. Suzanne Schubbert is funded by The Valley Foundation. in part by Parents Against Leukemia. 24 Dr. Warren Shlomchik, a Newman Family Scholar, is fully funded by The Newman Family. 16 Petter Woll, PhD Yubin Zhou, PhD Ravi Bhatia, MD John Crispino, PhD Varsha Gandhi, PhD Tomas Kirchhoff, PhD University of Oxford Immune Disease Institute City of Hope National Northwestern University University of Texas Memorial Sloan-Kettering Medical Center School of Medicine M.D. Anderson Cancer Center Cancer Center Jamie Wood, PhD Yubin Zhou, PhD* University of Minnesota, Twin Cities La Jolla Institute Smita Bhatia, MD, MPH Chi Dang, MD, PhD Celine Gelinas, PhD Susan Knox, MD, PhD for Allergy and Immunology Beckman Research Institute University of Pennsylvania UMDNJ – Robert Wood Johnson Stanford University Jennifer Woodard, PhD* of the City of Hope Medical School The University of Chicago Dimitrios Zisoulis, PhD Jayne Danska, PhD 29 Jeanne Kowalski, PhD University of California, San Diego Helen Blau, PhD The Hospital for Sick Children Irene Ghobrial, MD Johns Hopkins University Huafeng Xie, PhD Stanford University Dana-Farber Cancer Institute School of Medicine Dana-Farber Cancer Institute Lee Zou, PhD* Utpal Dave, MD Massachusetts General Hospital Bruce Blazar, MD Vanderbilt University Steven Gore, MD Donald Kufe, MD Wen Xue, PhD* University of Minnesota, Twin Cities Johns Hopkins University Dana-Farber Cancer Institute Massachusetts Institute James DeGregori, PhD School of Medicine of Technology TRANSLATIONAL RESEARCH Katherine Borden, PhD* University of Colorado at Denver Larry Kwak, MD, PhD 32 PROGRAM Université de Montréal Steven Grant, MD University of Texas Jianchang Yang, MD, PhD Gerald Denis, PhD The Translational Research Program Virginia Commonwealth University M.D. Anderson Cancer Center Nevada Cancer Institute supports outstanding investigations Vassiliki Boussiotis, MD, PhD Boston University Beth Israel Deaconess Jolanta Grembecka, PhD Suzanne Lentzsch, MD, PhD Tong Yin, MD, PhD deemed by our expert advisors Madhav Dhodapkar, MD most likely to translate basic Medical Center University of Michigan University of Pittsburgh Stowers Institute biomedical discoveries into new, Yale University for Medical Research safe and effective treatments, Kevin Brindle, PhD Monica Guzman, PhD 31 Ross Levine, MD Thomas Diacovo, MD ultimately prolonging and University of Cambridge Weill Medical College Memorial Sloan-Kettering Carol Ying, PhD Columbia University enhancing patients’ lives. of Cornell University Cancer Center Columbia University Patrick Brown, Dirk Dittmer, PhD* Johns Hopkins University Lori Hazlehurst, PhD Ronald Levy, MD Rushdia Yusuf, MD Iannis Aifantis, PhD University of North Carolina School of Medicine H. Lee Moffitt Cancer Center Stanford University Massachusetts General Hospital New York University at Chapel Hill & Research Institute School of Medicine Nicola Camp, PhD Shaoguang Li, MD, PhD Karl Zawadzki, PhD* Nicholas Donato, PhD University of Utah Xianxin Hua, MD, PhD University of Massachusetts Stanford University Raquel Aloyz, PhD University of Michigan University of Pennsylvania School of Medicine Lady Davis Institute Asher Chanan-Khan, MD Baochun Zhang, MD, PhD Gianpietro Dotti, MD* for Medical Research Health Research Incorporated Richard Jones, MD Daniel Link, MD Immune Disease Institute Baylor College of Medicine Stephen Ansell, MD Roswell Park Johns Hopkins University Washington University in St. Louis Ji Zhang, PhD Cancer Institute Division Dimitar Efremov, MD, PhD* School of Medicine Mayo Clinic and Foundation Mignon Loh, MD University of Pennsylvania International Centre for Genetic Preet Chaudhary, MD, PhD Craig Jordan, PhD University of California, Maria Baer, MD Engineering and Biotechnology Yanping Zhang, PhD University of Maryland, Baltimore University of Pittsburgh University of Rochester San Francisco University of North Carolina Martin Fernandez-Zapico, MD 26 Suning Chen, PhD Carl June, MD Lawrence Lum, MD, DSc at Chapel Hill Julio Barredo, MD Mayo Clinic and Foundation University of Miami Jiangsu Institute of Hematology, University of Pennsylvania Wayne State University Yu Zhang, PhD Soochow University James Ferrara, MD School of Medicine Kala Kamdar, MD Nadim Mahmud, MD, PhD Memorial Sloan-Kettering University of Michigan 27 Selina Chen-Kiang, PhD 28 Baylor College of Medicine University of Illinois, Chicago Cancer Center Pamela Becker, MD, PhD Weill Medical College Mark Frattini, MD, PhD 30 University of Washington Scott Kaufmann, MD, PhD Ari Melnick, MD Zhiguo Zhang, PhD of Cornell University Memorial Sloan-Kettering Mayo Clinic and Foundation Weill Medical College Mayo Clinic and Foundation Steven Bernstein, MD Cancer Center University of Rochester of Cornell University

26 Dr. Julio Barredo is funded in part 28 Dr. Selina Chen-Kiang is funded in 29 Dr. Jayne Danska is funded in part 31 Dr. Monica Guzman is funded in part * Newly awarded or renewed grants by The Gold-Diggers, Inc. part by Alexandra Mayes Birnbaum by The Bryce Foundation. by Robert and JoAnna Behl. in fiscal year 2012 and the New York City Chapter 27 Dr. Pamela Becker is funded in part 30 Dr. Mark Frattini is funded in part Board of Directors. by The James J. Reid, Jr. Family. by Lance Meyerowich and The Lymphomaniacs. 32 Dr. Larry Kwak is funded in part by Gerry Golub.

17 research grants (continued) research portfolios

Beverly S. Mitchell, MD Susan Rheingold, MD 33 Andrea Velardi, MD LLS Research Portfolios are groups Stanford University The Children’s Hospital University of Perugia of research projects organized 1 Acute Lymphoblastic Leukemia Research Portfolio is funded in part by of Philadelphia around a specific blood cancer Deborah Tobias – Translational Research Program. Steven Mittelman, MD, PhD Amit Verma, MD interest. The list below includes 2 Childrens Hospital Los Angeles Janet Rowley, MD 34 Albert Einstein College of Medicine donors that generously invested Acute Myeloid Leukemia and Myelodysplastic Syndromes Research Portfolio is funded in part by Hildegarde D. Becher Foundation, Inc., Frona A. Brown, The University of Chicago of Yeshiva University in a specific LLS research portfolio Markus Muschen, MD during this fiscal year. Ed.D, the Dallas Saint Valentine’s Luncheon and Fashion Show – In memory Children’s Hospital Los Angeles Dr. Felipe Samaniego, MD 35 Mariusz Wasik, MD of Tom Landry, The For Julie Foundation, Inc., The Hite Foundation, the Colin Jones Memorial Sports Foundation, King & Spalding, LLP, Neil Kishter, the University of Texas University of Pennsylvania Acute Lymphoblastic Leukemia 1 Steffan Nawrocki, PhD Douglas Kroll Research Foundation, Peter and Tina Locke, The Robert H. Lyon M.D. Anderson Cancer Center University of Texas Deborah White, PhD Leukemia Foundation, Clyde Smith McGregor and LeAnn Pedersen Pope – Acute Myeloid Leukemia and In Memory of Joan Kowing McGregor, Friends of the Ochs and Young Families, Health Science Center at San Antonio David Scheinberg, MD, PhD Institute of Medical Myelodysplastic Syndromes 2 The James J. Reid, Jr. Family, The Shimkin Foundation, Technology Concepts & Sloan-Kettering Institute and Veterinary Science Sattva Neelapu, MD Design, Inc., and an anonymous donor. for Cancer Research University of Texas Joseph Wiemels, PhD Chronic Lymphocytic Leukemia 3 3 Chronic Lymphocytic Leukemia Research Portfolio is funded in part by M.D. Anderson Cancer Center Aaron Schimmer, MD, PhD, University of California, the American Construction Co., Inc., Stephen and Madeline Anbinder, Paul and Helen Anbinder, Brian and Lisa Bee – Spin 4 the Cure, the Cora and FRCRC San Francisco 4 Owen O’Connor, MD, PhD Chronic Myeloid Leukemia John H. Davis Foundation, Imagine a Cure for Leukemia, Jonathan and University Health Network New York University Dr. B. Hilda Ye, PhD 36 Robin Klein, Harry and Edith Klein, the Lumina Foundation, Marie McDemmond, School of Medicine Chantal Séguin, MD Albert Einstein College of Medicine Hodgkin Lymphoma 5 and an anonymous donor. McGill University 4 Chronic Myeloid Leukemia Research Portfolio is funded in part by Imagine Robert Orlowski, MD, PhD* Qing Yi, MD a Cure for Leukemia, Larry and Leslie Nance, and James and Judith Wilson. University of Texas Jonathan Serody, MD University of Texas Myeloma and Waldenstrom 6 5 M.D. Anderson Cancer Center University of North Carolina M.D. Anderson Cancer Center Macroglobulinemia Hodgkin Lymphoma Research Portfolio is funded in part by Alex and Janet Boggs, Donald Porteous, and Kickin’ The Cancer Blues/Liz Bohman Hospitals Foundation. Samir Parekh, MD Andrew Zannettino, PhD Aggressive Non-Hodgkin Albert Einstein College of Medicine Rita Shaknovich, MD, PhD Institute of Medical Lymphoma 7 6 Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded of Yeshiva University Weill Medical College and Veterinary Science in part by Rae Berger, the Carlson Family Foundation and the Names Family of Cornell University Foundation. Leonidas Platanias, MD, PhD Fenghuang Zhan, MD, PhD Indolent Non-Hodgkin 7 Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part Northwestern University Motomu Shimaoka, MD, PhD University of Utah Lymphoma 8 by Creative Escape/Bazzill Basics Paper and the Slice of Lime Foundation. School of Medicine Immune Disease Institute Patrick Zweidler-McKay, MD, 8 Pediatric and Young Adult Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part Josef Prchal, MD Varda Shoshan-Barmatz, PhD PhD by Timothy and Christine Lindenfelser, Jerry and Lois Rosenblum and Blood Cancers9 University of Utah Ben-Gurion University of the Negev University of Texas an anonymous donor. M.D. Anderson Cancer Center 9 Pediatric and Young Adult Blood Cancers Research Portfolio is funded in part Miles Prince, MD Alexander Stewart, MD 10 Quality of Life by Brian and Lisa Bee – Spin 4 the Cure, the Thomas and Agnes Carvel University of Melbourne Mayo Clinic and Foundation Foundation, EFESTE Winery, The Gap Foundation, The Gold-Diggers, Inc., Lee Ratner, MD, PhD Samuel Strober, MD Stem Cell Transplantation 11 The Jeff Gordon Foundation, Karyn Research Fund, the Michael W. McCarthy Foundation, Hockey Fights Cancer, Francis X. and Susan Reinhardt, Melissa Washington University in St. Louis Stanford University Segal, and Mike and Claire Shevlin – Links For Leukemia. Therapy Acceleration Program 12 Pavan Reddy, MD John Timmerman, MD 10 Quality of Life Research Portfolio is funded in part by Hildegarde D. Becher University of Michigan University of California, Los Angeles Foundation, Inc., Greg and Michelle Becker, The Escher Foundation, Hamill Waldenstrom Family Trust, the Douglas Kroll Research Foundation, Mike and Kathy Ladra, Robert Redner, MD Francisco Vega, MD, PhD Macroglobulinemia Initiative 13 the Morrison-Minton Family Trust, and Guy and Linda Nohra. University of Pittsburgh University of Texas 11 Stem Cell Transplantation Research Portfolio is funded in part by The Bryce M.D. Anderson Cancer Center Foundation, Kevin and Keri Cameron, The For Julie Foundation, Inc. and Michael and Elizabeth Sweeney. 12 Therapy Acceleration Program is funded in part by Bruce Bocina, The For 33 Dr. Susan Rheingold is funded in part * Newly awarded or renewed grants Julie Foundation, Inc., John Kellenyi, Patrick and Nancy Minan, Jerry and Lois by Mike and Claire Shevlin - Links in fiscal year 2012 Rosenblum and The Roderick Seward, Flossie Radcliffe & Helen M. Galloway for Leukemia. Foundation. 34 Dr. Janet Rowley is funded in part 13 Waldenstrom Macroglobulinemia Initiative is fully funded by Peter Bing, 36 by The Pamela B. Katten Memorial Dr. B. Hilda Ye is funded in part International Waldenstrom Macroglobulinemia Foundation, and the Steven Leukemia Research Foundation and by Lance Meyerowich and The and Michele Kirsch Fund, an advised fund of the Silicon Valley Community the Dr. Scholl Foundation. Lymphomaniacs. Foundation. 35 Dr. Felipe Samaniego is funded in part by The Fledgling Fund.

18 Medical & Scientific Professional Education Advisors Subcommittee

Chair Jorge Cortes, MD Catriona Jamieson, MD, PhD Chair Brian Druker, MD The University of Texas University of California, San Diego Howard Hughes Medical Institute Armand Keating, MD Irwin Bernstein, MD M.D. Anderson Cancer Center Oregon Health & Science University Princess Margaret Hospital Susan M. O’Brien, MD Fred Hutchinson Cancer Cancer Institute Research Center Vice Chair James H. Davis, PhD, JD The University of Texas Human Genome Sciences, Inc. M.D. Anderson Cancer Center James Griffin, MD Curt I. Civin, MD Dana-Farber Cancer Institute University of Maryland Brian Druker, MD Derek Raghavan, MD, PhD School of Medicine Howard Hughes Medical Institute Carolinas HealthCare System Armand Keating, MD Oregon Health & Science University Princess Margaret Hospital Franklin O. Smith, III, MD Cancer Institute Frederick Appelbaum, MD Cincinnati Children’s Hospital Franklin O. Smith, MD Fred Hutchinson Alan Gewirtz, MD Medical Center Cincinnati Children’s Hospital Cancer Research Center University of Pennsylvania, Medical Center Nancy Speck, PhD School of Medicine Irwin Bernstein, MD University of Pennsylvania, Nancy Speck, PhD Fred Hutchinson D. Gary Gilliland, MD, PhD School of Medicine University of Pennsylvania Cancer Research Center Merck & Co., Inc. School of Medicine Steven Bernstein, MD James Griffin, MD University of Rochester Dana-Farber Cancer Institute Medical Center Mary Horowitz, MD Alexandra Mayes Birnbaum Medical College of Wisconsin Peartree Publishing

Endowment Funds

The Bill Beattie Memorial Endowment Fund (Alberta) Jim Jacobs Leukemia Research Fund

Mary & Robert Bronstein Memorial Fund The Rachel Kudish Fund

The Virginia Major Brooks Memorial Endowment Fund Jane Elissa/Charlotte Meyers Endowment Fund

de Villiers Endowment Fund The Rae Endowment Fund (Ontario)

Thomas M. Ford Memorial Fund Vrushali Ranadive Fellowship Fund

GlaxoSmithKline Foundation - Gertrude B. Elion Endowment Fund Reich Endowment Fund

GlaxoSmithKline, Inc. Research Fund The UFCW (Canada) Endowment Fund

19 Donors

The below listing is made up CA Technologies Mercedes-Benz USA, LLC CareFirst BlueCross BlueShield New York City Chapter Aetna Foundation of individuals, foundations and Board of Directors corporations that generously California Community Foundation* Metzger Law Group Carlson Family Foundation* Alaska Airlines supported LLS’s mission during Carter’s, Inc. Nike CIQ Online New York Community Bancorp, Inc. Alberto Culver Company this fiscal year. Citi The Orokawa Foundation Citrix Systems Northrop Grumman Alcatel-Lucent Onyx Pharmaceuticals, Inc. PS $1,000,000 and Above City of Tempe Pfizer, Inc. C Clear Channel Radio, San Francisco Alice Ann Bien Memorial The Beer Store Coach Foundation, Inc. PVH CN Philadelphia Multiple Foundation Myeloma Networking Group Burlington Coat Factory Community Health Charities Donald Porteous Community Health Charities Eric Allen PhRMA C Celgene Corporation PS C R of New England of Minnesota Alliance Data Systems, Inc. Quest Diagnostics, Inc. C PricewaterhouseCoopers LLP Centers for Disease Control Credit Suisse Rally Foundation for Childhood Computer Associates, Inc. Allied World National PS Remillard Family Foundation and Prevention* PS Dallas Saint Valentine’s Luncheon Cancer Research* Enterprise Holdings Foundation * Allstate Genentech, Inc. PS PP C and Fashion Show Runner’s World Ernst & Young LLP RMD Corporation The Altschul Foundation – The Harry T. Mangurian, Jr. DialAmerica Edward Robinson Reichman Memorial Sanofi Aventis PS Florida Department of Corrections Foundation, Inc.* Elbit Systems of America, LLC Security Service Federal The For Julie Foundation, Inc. Richard and Nancy Rogers American Construction Co., Inc. Millennium: The Takeda Oncology GlaxoSmithKline PS C Credit Union Safeway, Inc. AMERICAN SYSTEMS Company PS C R Gap, Inc. Google Stater Bros. Markets Sallie Mae, Inc. America’s Charities Novartis Pharmaceuticals, Inc. PS Garden City Turkey Trot The Jeff Gordon Foundation Joseph S. and Diane H. Steinberg Sarver Charitable Trust Paul and Helen Anbinder The Olive Garden Italian Restaurant GEICO The Greene Team Charitable Trust* The Victor E. & Caroline E. Schutte Stephen and Madeline Anbinder Joseph C. Sanfilippo Global Traveler Hockey Fights Cancer Deborah Tobias* Foundation – Trust E Anning-Johnson Memorial Fund* Walter and Beth Grant* UnitedHealthcare Siemens The Paul E. Singer Family HPD Bicycle Relay Team Hargrove Anthem Blue Cross and Blue Shield Foundation* Vistar Corporation Sysmex America, Inc. IHOP Leon W. (Pete) Harman AOL, Inc. United Food and Commercial The Walmart Foundation Toyota Imagine a Cure for Leukemia HealthONE Apache Corporation Workers Union (UFCW) Wells Fargo TRIB Total Media Jack’s Mannequin-Dear Heavin Family Foundation Arizona Diamondbacks United Food and Commercial Jack Foundation Anonymous (3) TUAC Québec Art Van Furniture Workers International Union The Hollander Foundation The Jim Jacobs Charitable Murray Tuttleman (Canada) IEP – MPG Asbury Automotive Group Foundation $50,000 ~ $99,999 UBS Financial Services Prescott Ashe Karyn Research Fund* Adobe Systems Incorporated Industrial Alliance Pacific $500,000 ~ $999,999 The Valley Foundation ATR International The Pamela B. Katten Memorial Air Products and Chemicals, Inc. Iowa Select Farms Foundation Cephalon Oncology PS C Wilson Farms, Inc. Auburn Creek Limited Partnership Leukemia Research Foundation American Airlines Just Give The Gap Foundation Anonymous (2) AutoCricket Corporation Sydney and Isobel Kemper* American Electric Power Laborers’ International Union Susan Lang Foundation* F.M. Kirby Foundation* of North America AutoTrader.com Amgen C $10,000 ~ $49,999 Rush Limbaugh Steven Lieblich Baker Botts, LLP The Steven and Michele Kirsch The Barker Family – 20/20 Research, Inc. The Newman Family* Fund, an advised fund of the In loving memory Lighthouse Investment Partners, LLC Baker Tilly Silicon Valley Community 610 Stompers of Christian Barker Lunardi’s Markets Banco Popular Foundation* $100,000 ~ $499,999 97.1 WASH-FM The Beck Family Foundation Todd McClintock Memorial Bank of America Allos Therapeutics, Inc. PS C R Neil Kishter* ABM Janitorial Services Brian and Lisa Bee – Spin 4 the Cure Research Fund The Bank of New York Mellon Austaco, Ltd. Douglas Kroll Research Foundation John Abraham Rae Berger Merchants Bonding Company Bank of Tokyo-Mitsubishi UFJ Barclays Capital Timothy and Christine Lindenfelser* Accenture Big Steaks Management, LLC Michael C. Fina Barclays Bank Delaware The Robert H. Lyon Anthony Acri The Stephen Birnbaum Foundation* Microsoft Corporation Leukemia Foundation Blue Cross and Blue Shield Bard/Access Systems Ann Adams Booz Allen Hamilton of Alabama Microsoft Corporation Clyde Smith McGregor Bare Escentuals Matching Gifts Program Adeler Jewelers Bristol-Myers Squibb Company and LeAnn Pedersen Pope – BMC PS C Agnes Barrett In memory of Joan Kowing BTIG, LLC Mike Hunters Team ADP McGregor Barrett Family Foundation 20 BASF, The Chemical Company Robin Bowser Capitol File Magazine Clarks Community Health Charities Delta Health Systems Lee Bates BP Fabric of America Fund Capstone Advisory Group, LLC The Classic Catering People of Maryland Megan Demers Carlos Batista Foundation John Brandone CARFAX, Inc. Cleary, Gottlieb, Steen Community Health Charities John DeRosa of Michigan Stephen Bauer Bravo Sailing Corp. The Caring Foundation & Hamilton, LLP Deutsche Bank Bruce and Isobel Cleland Community Health Charities Bavaria Yachts USA Brayton Purcell Carroll Combs Memorial of New York DLA Piper, LLP Bayada Nurses Alan and Ellen Breed Golf Classic Cleveland Society for Human D-Man Festival Resource Management Community Health Charities BD Biosciences Bridgelux, Inc. Don and Linda Carter of Texas Dominick’s CoActiv Capital Partners BDO USA, LLP Bridgewater Associates, LP Pete Caruso – City Contracting Community Health Charities Doosan Infracore America Thomas and Agnes Carvel The Cornelius J. Coakley Family of Virginia Corporation Hildegarde D. Becher Peter and Janice Brock Foundation Foundation, Inc. Foundation Curtis Compton Duff & Phelps Broward Health Alan Cohen Greg and Michelle Becker Caspe Foundation CSC Edward B. Dunlap, Jr. Foundation Frona A. Brown, Ed.D. The Coleman Foundation The Bell Family Foundation James and Anita Cauley Consolidated Carpet Eastport Yacht Club, Ltd. The Brown Family Steve and Doris Colgate Bell Family Trust Causemedia Group Alverin M. Cornell Foundation E Construction Group, Inc. Brown & Gould, LLP Columns Resource Group CB Richard Ellis Costco Wholesale Bell Microproducts Brownstein Hyatt Farber Foundation, Inc. Ed Voyles Automotive Group Celator Pharmaceuticals Corp. C The Belvedere Cove Foundation Schreck, LLP Combined Health Agencies Ven Cote EFESTÉ Winery Centene Foundation Bert Smith & Co. Patricia Brumley Comcast CPM Consulting James L. Eichberg Foundation, Inc. Central Blood Bank BF Communications Lewis Brunswick & Rebecca Matoff Commerce Bank Crane Fund for Widows and Children Steven Eisenstadt Foundation, Inc. CFACQ BGR Group, LLC Community Blood Center/ Creative Escape/Bazzill Basics Paper Diane Elalouf The Bryce Foundation CGI Federal Big Lots Stores, Inc. Community Tissue Services Credit Suisse Americas Foundation Eli Lilly and Company C Clyde and Rosie Billman Buchanan Ingersoll & Rooney, PC CGI The Community Foundation Creekside Middle School EMC Corporation Temple Hoyne Buell Foundation CH2M Hill for the National Capital Region Biogen Idec C Crescent Beach Challenge Emergent BioSolutions, Inc. The Community Foundation BioMed Realty Trust, Inc. Jeff Burch – Hot Ticket Racing Chapdelaine & Co. Crowe Horwath, LLP Emerson Fluid Systems of North Texas BioSolutions, Inc. Tom Burke 3-on-3 Basketball Charles A. Klein & Sons, Inc. Cruise Industry Charitable Dick Enersen The Community Foundation Tournament Charles Schwab Foundation Foundation Ricardo Bird of West Alabama Englefield Oil Company Burns & McDonnell Foundation Chartis Insurance CTB/McGraw-Hill, LLC Alexandra Mayes Birnbaum Community Health Charities The Enrichment Foundation Butler Family Foundation Dabb Energy Company Bisnow The Rhoda and David Chase Family of Arizona Enterprise Rent-A-Car C & J Viner Family Foundation Foundation, Inc. DaHunt For The Cure, LLC Leon Black Community Health Charities Epsilon Data Management, LLC Caesars Foundation Chevron of California Dallas Stars Foundation The Blackstone Charitable Equipment Leasing Foundation Dillon Cameron Chiaramonte Construction Company Community Health Charities Danford Foundation and Finance Association of Colorado Bloomberg Kevin and Keri Cameron Chicago Fire Foundation DARCARS Equity Office Community Health Charities blue moon fund Anthony Campbell Children’s Mercy Hospitals John Dauer & Clinics of Florida Blue Shield of California Matthew Campbell Cora and John H. Davis Foundation Betsy Choate Community Health Charities BlueCross BlueShield of Mississippi Canaccord Genuity Corp. of Georgia Donald and Leona Davis Chris’ Wish Pharmaceutical The Cancer Institute Davis Polk & Wardwell, LLP The Blumenfeld Family Community Health Charities Funding Legend of New Jersey Foundation Justin Chueh of Illinois Bruce Bocina DC Rental PS Patient Services/Education Cancer Treatment Centers Cristina Cinquanta Community Health Charities Catherine Bodenstedt of America Dekalb School Employees PP Public Policy Cintas of Iowa Foundation, Inc. Alex and Janet Boggs Samuel C. Cantor Charitable Trust C Campaign Citi Corporate Community Health Charities Dell Giving Program Herman and Emmie Bolden Trevor Capiccioni and Investment Banking of Kansas & Missouri R Research Dell, Inc. Boston Millennia Partners Capital One Bank Jay and Susan Clark – Carbide Community Health Charities * Denotes multi-year commitment Concepts Company, LLC of Kentucky Deloitte LLP

21 Donors (continued)

The Escher Foundation G&T Sports Medicine GTDS, Inc. iContact John Kellenyi Small Business Advisors/ ESPN Courtney Knight Gaines H&D Mechanical, LLC Ida Price Middle School Kent’s 5K Run Lighthouse Insurance Services Foundation, Inc. John Esposito Hamill Family Trust Independence Blue Cross Ellen Perlow Kessler Lincoln-Way Community Galen College of Nursing High School Kesha Evans Jeff and Deb Hansen Independent Health Charitable Foundation Garden Meadows Ladies Sam and Gail Lindenberg Evans Tool and Die, Inc. Harari Family Charitable Trust ING Investment Management Key Banc Capital Markets Golf Tournament Family Foundation Frank M. Ewing Foundation, Inc. Harkins Builders InkHead Promotional Products Kickin’ The Cancer Blues/ The Bill & Melinda Gates Liz Bohman Foundation List Innovative Solutions F.A.L.L. Classic Caroline J. Harmon Irrevocable Trust Insulators Health Hazard Fund Foundation King & Spalding, LLP Joseph Littenberg FarmerMac Gaylord Entertainment Foundation Harrah’s North Kansas City Hotel Intellectual Ventures Michael Lizura and Casino Management, LLC The Klein Family Foundation, Inc. FARO Technologies, Inc. GE Capital Peter and Tina Locke Susan Hausler – The International Society Harry and Edith Klein Darin Ferguson GE Capital, Healthcare Lockheed Martin Corporation In memory of Bebe Fineman J&B Restaurant Partners, Inc. Jonathan and Robin Klein Lorenzo Fertitta Financial Services Heather Locklear HCA / TriStar Division J.T. Tai & Co. Foundation Knights of the Grip Fidelity Charitable Gift Fund GE Foundation Longbranch Lakes Properties, LLC HCA Midwest Health System The James Cancer Hospital Kohl’s Denis Filiatrault GEICO Philanthropic Foundation Headstrong Foundation and Solove Research Institute KPMG LLP Louisville Christian Foundation Dr. Frank A. and Wendi L. Finazzo General Dynamics Information Angelo and Karen Lucrezia Technology Jim Healy Charitable Gift Fund Jared Coones Pumpkin Run/Walk Charles and Lynda Kraemer The Fine & Greenwald H-E-B JDP Mechanical, Inc. Lumina Foundation Foundation, Inc. Georgia Power Foundation, Inc. Mark and Christine Kraemer Mark Heleen J.E. Richards Lundbeck, Inc. The Cortland Finnegan GetWellNetwork, Inc. Warren Kreter Lukas Lundin ARK 31 Foundation Tony Giachinta The Helis Foundation Virginia Sheldon Jerome Foundation Kristen Garvey’s Beef and Beer Lynd World Grace J. Fippinger Foundation Giannoulias Hospitality Bruce and Dana Hendin Jim Koons Automotive Companies Kritchman Family Foundation, Inc. M&T Bank Simon C. Fireman Charitable Giant Food Stores Herbert Homes, Inc. John Thomas Financial Scott Krueger Foundation M&T Charitable Foundation Gibson, Dunn & Crutcher LLP Highmark BlueCross BlueShield Violet M. Johnson Family KST Data, Inc. Fishing Bay Yacht Club, Inc. Foundation Mack Madness Peter and Ann Gilbert Highstar Capital Anthony Kubala Fitzgerald Family Foundation Johnson & Johnson Macquarie Group Foundation Tom and Laura Gilbert Glen Hilliard Bonnie Kurtzman Colin Jones Memorial Sports The Fledgling Fund The Hite Foundation Ladish Co. Foundation Edward G. & Kathryn E. Mader Glimcher Realty Trust Foundation Foundation Florentine Camenisch Foundation HITT Contracting, Inc. Mike and Kathy Ladra The Gold-Diggers, Inc. David Jones The Mammel Foundation Foley & Lardner, LLP Hogan Lovells LaFontaine Automotive Group Goldman, Sachs & Co. Ralph and Sally Jones The Samuel P. Mandell Foundation FoxKiser The Home Depot Foundation Don C. and Diane S. Lake Family Gerry Golub Julian Ceramic Tile, Inc. Peter and Gina Manos John & Mary Franklin Foundation Honeywell Hometown Solutions Lamphere Consulting, Inc. Pearl Goodman Gerald Kafka and Rita Cavanagh Manthropy – David Frantze Michelle Lunn Hope Foundation Dave and Joni Lang Reuben and Mollie Gordon Stanley and Sandra Kahan A Date for Goodness Sake Fraser High School Foundation Horizon Heating Cynthia Langley Kaiser Foundation Health Plan Market Focus, Inc. The Jack French Family Gore Design Completions, Ltd. Doug and Jennifer Houser of Georgia, Inc. Lantana Education Bill Martin Virginia Frieze Charitable Foundation Grand Chapter O.E.S. of Wisconsin The Howard Family Foundation Kaiser Permanente Foundation Karen Mashkin Paul and Carol Frimmer Health C W. Robert Lappin Great American Insurance Group HSBC Massapequa Youth Lacrosse The FRS Company Latham & Watkins, LLP Great Harvest Bread Company Human Genome Sciences, Inc. Daniel and Susan Kane Lisa Massar FTI Consulting, Inc. Caleb Lawrence Greater Milwaukee Foundation, Inc. Bruce & Priscilla Hutchins Family Dan Kaplan David and Arlene Massimalla FTI Great Charity Challenge Legacy Endowment Leder Family Foundation Greenberg Traurig, LLP The Karches Foundation Matthew’s Miracle Fulbright & Jaworski, LLP HVAC Concepts, LLC The Len-Ari Foundation, Inc. Greenstar Recycling Adam and Diane Katz Harold Matzner J.B. Fuqua Foundation Hy-Vee, Inc. Brian Levine The Holland C. Gregg IV Gary and Rochelle Katz Maureen’s Mile Beef and Beer Furniture Fair Research Program IBC Bank Ken and Barbara Lieberman Keane Charitable Group Maxim Group, LLC Eva Griffith ICAP Services North America, LLC Christopher Kearns LifeSource

22 Maxim Integrated Products Mitsubishi Power Systems The New York State Department PGA Tour, Inc. Raytheon Company Christopher Russell Carl and Pinkie Mayfield Americas, Inc. of Taxation and Finance PGT Trucking, Inc. RBC Capital Markets RW Scaife Mayo Foundation Alan Mittleman Kenneth and Bonni Newton Pharmaceutical Care RCS Investment Group, Inc. Jeff and Pat Sachs Michael W. McCarthy Foundation Mizuho Corporate Bank, Ltd. Nicholas Family Foundation Management Association Reach John and Lauren Salata Mary E. McCaul Modell’s Sporting Goods No Frills Supermarkets Lawrence Pidgeon Real Estate Board of New York Salesforce.com Foundation Ralph H. & Ruth J. McCullough Lori Mody Guy and Linda Nohra Piedmont Healthcare Real Estate One Charitable Salt River Pima-Maricopa Indian Foundation Monterey Peninsula Foundation Northside Hospital Pietro’s Restaurant Group Foundation Community/Casino Arizona Marie McDemmond Moody Foundation Northwestern Mutual The PIMCO Foundation Helen Reed The San Francisco Foundation The June & Cecil McDole Harry C. Moore Foundation Northwestern Mutual – Ping Y. Tai Foundation Lisa Reed SanDisk Corporation Charitable Fund Morgan Borszcz Consulting The Tronco Financial Group Philip D. Pitchford The James J. Reid, Jr. Family Sandra Atlas Bass & Edythe McIntosh Properties, LLC Morgan Keegan & Company, Inc. Norton Cancer Institute Plaid Pantries, Inc. Francis X. and Susan Reinhardt & Sol G. Atlas Fund, Inc. McKinsey & Company, Inc. Morgan, Lewis & Bockius, LLP Ober|Kaler PlanningFamily.com Renaissance Charitable Sanmina-SCI Corporation McKinstry Morgan Stanley Smith Barney, LLC Occidental Petroleum Corporation Craig and Marie Platenberg Foundation, Inc. SAP America, Inc. The McMahan Family MorganFranklin Corporation Friends of the Ochs PNC Bank Rerum Novarum Charitable Trust Sarah Cannon Research Institute Charitable Foundation and Young Families Bob and Michele Morris Howard Polk James Resnick Christina Saunders The Gerald and Paula McNichols The Offterdinger Family Jim Morrison Memorial Polk Foundation Margaret Reynolds John and Mary Louise Scanlan Family Foundation Lauzon O’Halloran Foundation Basketball Jam Polo Ralph Lauren Foundation Rhulan Rock Hill Run & Ramble Phillip and Heather McWane Oklahoma University Medical Center Stephen Scherr Morrison-Minton Family Trust Lisa Pontecorvo Nina Richardson Mechanical Contractors Association The W. O’Neil Foundation The Marge & Charles J. Schott of New York, Inc. Morristown Financial Group John Ponterio Leukemia Benefit Riemer & Braunstein, LLP Oracle Foundation Mechanical Incorporated MTCI Powell Industries Rite Aid Foundation Peter O’Sullivan The Victor E. & Caroline E. Schutte MedImmune, Inc. Elizabeth Mungo PR DC RoadID, Inc. Foundation – 1959 Others First Medtrak Services, LLC Barry Murphy Pragmeering Corporation Robert Michael Schwab Charitable Fund Ourisman Chantilly Imports, Inc. Communications, Inc. MEMC Electronic Materials, Inc. Jerome S. and Grace H. Murray Prairie Meadows Edith M. Schweckendieck Trusts Foundation Oxford Development Company Mrs. Edgar A. Robinson The Memorial Foundation The Pray Family Foundation Scotia Capital Joseph Naggar The Pampered Chef Rock Point Associates, LLC Memorial Healthcare System Theresa Precopio Scott Safety The Harvey E. Najim Family Parents Against Leukemia Rogers Family Foundation Merck C Presbyterian Cancer Center Seagate Technology, LLC Foundation Park Place Motorcars Dallas Rope for Hope Merck Sharp & Dohme John and Monika Preston Sedano’s Supermarkets Nalley Automotive Group Patrick Park Roper St. Francis Healthcare Meredith Corporation Foundation Price Chopper Supermarkets William Sefton Names Family Foundation Passport Capital Jerry and Lois Rosenblum Merrill Lynch Procter & Gamble/Cub Foods Melissa Segal* Larry and Leslie Nance Pasta, Inc. Sandra Rosenthal Merrill Lynch Wealth Management/ Providence Health Systems – Sempra Energy Foundation National Cooperative Services Paul Hastings LLP The Rosenthal Companies, Inc. Bank of America Corporation Anchorage Peake BMW Rotary Club of Nipomo James A. Mesko Foundation National Gypsum Company Province of BC Pen Air Federal Credit Union The Royal Bank of Scotland Lance Meyerowich National Philanthropic Trust Prudential Financial, Inc. Pharmaceutical Microlink, LLC Peoples Natural Gas RR Donnelley National Rural Utilities The Quinn Law Firm Funding Legend Pepco Holdings, Inc. Paul and Joan Rubschlager Mighty Taco, Inc. Cooperative Finance Corporation Rabobank PS Patient Services/Education The Steven M. Perez Foundation Foundation Milbank, Tweed, Hadley Dan and Martha Nealon Radio Flyer PP Public Policy & McCloy LLP Mr. and Mrs. Ross Perot Ruby Restaurant Group NetApp Radio-Canada, Paquet Voleur C Campaign Patrick and Nancy Minan Runners for Life The Netter Family Foundation Perry-Smith LLP Rancho Sante Fe Foundation R Research Ed Miner Running Zone Foundation Neurological Institute of Savannah Ronnie Pertnoy The John G. Rangos, Sr. Family Suzy Minkoff & Center for Spine, PC Pete Moore Imports Charitable Foundation Rural Telephone Finance * Denotes multi-year commitment Cooperative 23 Donors (continued)

The Roderick Seward, Flossie SRA International Tiber Creek Partners, LLC VCU Health System Wheeler Family Top Campaign Fundraisers Radcliffe & Helen M. Galloway St. Joseph’s Candler Tickets.com, Inc. Soo Venkatesan Charitable Foundation Schools that have raised more Foundation John White than $25,000, individuals who St. Vincent de Paul Foundation, Inc. Title Associates Verigy US, Inc. have raised more than $50,000 Carl Sewell Stanley Korshak The TJX Companies, Inc. Verizon White & Case, LLP or company teams that have raised SF Foundation more than $100,000 to support Starbucks Corporation Toll Brothers Vibra Healthcare White Castle LLS’s mission. Cornelius Shannahan State Street Touchstone Energy Cooperatives Bradley Vick The Whitney Foundation Eric Allen The Earl and Brenda Shapiro Whole Foods Market Foundation Deborah Stephen Towers Watson Lois Vick Sandy Allen-Bard William E. Carter Company, Inc. The Shawver Family Sterling Mets LP Transwestern Sena Vick Revocable Trust Toby Alvares James and Judith Wilson Mike and Claire Shevlin – Lorna Stokes Trion Group Joseph and Drenda Vijuk Foundation Austaco, Ltd. WIVB-TV, Channel 4 Links for Leukemia Stormont-Vail HealthCare Trippin’ For A Cure Vitas Innovative Hospice Care Barclays Capital The Shimkin Foundation Viola Strutz Joseph F. Troy Fund Rhonda Vredenburg Richard and Kaye Woltman Erin Barfels ShopRite Suffolk Construction for Leukemia Research W. W. Grainger, Inc. WTOP Radio Ruth Bartlett Showtime Networks, Inc. Sullivan & Cromwell, LLP Truland Service Corporation Scott Walker and Laura Quay Carol Wu Matthew Baumgartner Sick Kids Charitable Giving Fund SunDun Office Refreshments The Trust Company of the South Walmart Community Giving Daniel H. Wu – Cromwell Baun In loving memory of Anita Wu Silicon Valley Financial Group Frank and Judy Sunberg Robert and Jane Tschudy Walmart Stores, Inc. James Becker WUSA9 Francesca Billups Mannix John Silvestri SunTrust Banks, Inc. Tube City IMS Theodore Wang Daniel Wyner The Blackstone Group Dr. Jesse L. Simon Charitable SuperGen, Inc. Turner Interiors Washington Area Toyota Dealers Foundation Yahoo! Employee Foundation Michael Blaser SureTec Turner Special Projects Division Association, Inc. The Sidney, Milton Mina Yanney Booz Allen Hamilton Sutter Health Jack A. Turpin Washington Business Journal & Leoma Simon Foundation Yollick Law Firm, PC Donald Boyajian Michael and Elizabeth Sweeney UBS Securities, LLC Washington Convention Center Charles Sisca John and Adelaide Zabriskie Jason Brian Sweet Ovations UCSF Medical Center Washington Gas Skunk Train Ziolkowski Patent Solutions British Airways Michael Sweig Foundation UGL Services – Equis Operations Washington Post & Cars.com Sleepy Hollow Physical Therapy Group, SC Burlington Coat Factory Synopsys, Inc. UK HealthCare Washingtonian Slice of Lime Foundation Joseph Zvesper CA Technologies Takeda Pharmaceutical Ultimate Software Wasie Foundation Smigel, Anderson & Sacks Anonymous (17) Jackie Carey Company Limited C Unanet Technologies Bill and Denise Watkins Douglas A.and Phyllis Smith Brandon Carone Tarditi Family Unite Here Local 47 Watkins Meegan LLC Elaine Smith Carter’s, Inc. Target Corporation United Association Wawanesa Insurance Company CGI Technologies Michael and Iris Smith TAS Foundation United Service Association WebMD Health Foundation Citi Smith Productions for Health Care Technology Concepts & Design, Inc. WebMD, LLC Coach, Inc. Barry and Meredith Snader United States Steel Corporation Tennessee Oncology, PLLC Wechsler/Marsico Associates Michael Conlon Howard Sokolowski United Way of the National Texas Instruments Inc. Weill Cornell Medical College, Tom Connelly Gloria Somerville Wagner Capital Area Jenni Thimesch Hematology/Medical Oncology Bob Coven Sorgente Group Foundation, University of Kansas Medical Center Michael Thomas The Harry & Jeanette Weinberg Credit Suisse Institute for Art and Culture The University of Michigan Foundation, Inc. Pharmaceutical Mrs. Gillis Thomas Funding Legend Lacey Dalcour Salas Southeast Nebraska Cancer Center UPMC Wells Fargo Foundation PS Ray Davis Thompson Habib Denison (THD) Patient Services/Education Southern California Gas Company The UPS Foundation West Fraser Mills Ltd. PP Public Policy Deloitte LLP The Stewart and Jean Thompson Southwest Convenience Stores Utica Community Schools West Penn Allegheny Health System Children’s Foundation C Campaign Justin Dobbs The Spangenberg Foundation Valero Energy Foundation Westchester County Detective Thorp Reed & Armstrong, LLP R Research Tommy Dupuis Association Spire Corporation Vanderbilt-Ingram Cancer Center Elbit Systems of America Thrifty Car Rental The Frederick and Margaret L. Sprint Vanguard Charitable Endowment * Denotes multi-year commitment Ernst & Young LLP Edgar A. Thronson Foundation, Inc. Program Weyerhaeuser Foundation 24 LEgacy Circle

Alberto Fernandez The Lymphomaniacs Kimarie Stratos Legacy Circle honors those who Jacqueline Hood* Jeff Pollock designate LLS as a beneficiary Drew Martin Larry Taylor, Dr. Frank A. and Wendi L. Finazzo, of their will, trust, retirement Thomas Istrico Alan Propst* Winning Smiles Custom Dentistry Jennifer Martin Merchants Bonding Co. account or insurance policy, Raymond Jackson* Rade Ratkovic* G-Form, LLC Team Blumenfeld or enter into a charitable gift Catherine Matous annuity. We list our newest Annie Jones* Marie Ray* Kyle Garlett Matt Mausser Team Gage members below along with those Dawn Gates Team WillyK whose bequests of $10,000 Jill Elizabeth Judson Frank Renald Sherri McElhaney or more were received this year. Jennifer Giannini Lance Meyerowich Kim Tindall Phyllis Katsikas Ruth Repko* Kostas Giannoulias Alex Tronco Thomas Angelo Michael C. Fina Marcia Keller* Donald Riskind* Tony Goff Mighty Molars Triana Trujillo Marjorie Annin* Catherine Kinser* Elizabeth Rockefeller* Rosemary Gong Jerry Truman Marnie Miller Jill Archer Google Chris and Kath Tsakalakis Maria Kitzmiller* Erick Rohde Dr. Joseph O. Moore Susan Avery* Thomas Graham Kevin Morgan Steve VanGorder John Kohler Evelyn Sanguinetti* Lorraine Azrak* Matt Graybill Marcie Morrison Ana Vento Aaron & Patricia Konstam Richard Scharff* The Greene Team Bradley Vick Joan Bailey* Mount Pisgah Christian School Seymour Lavine* Ken & Carolyn Schmalenberger Maryanne Guido Vistar Louise Barrows* Dr. Ruben Niesvizky Molly Levitis* Harry M. Schultz* Annmarie Hagan Novartis Pharmaceuticals, Inc. Waddell & Reed Caroline Beauchamp Summer Hall Walter Johnson High School Richard A. Lieboff, Ph.D. Norman Shapiro* Ian O’Malley* George Becker* Threase Harms Warren High School, Sam & Gail Lindenberg Evelyn Shook* Oak Point Intermediate School Betty Birk* David Hili Downey, CA Partners Mortgage Helen Lippert* Thorbjorg “Toby” Slusser* Donnie Hill The Warriors Joan Booth* Steven Pauli-Simonpietri Jay London* April Smith* Brian Waterman Amanda Holland Kay Bowers* Kevin Pearson Betty McClure Inez Starr* Houston Police Bicycle Relay Team Watertown Middle School Jeff Peppet Margot Brodke Josie Hubschman Wells Fargo Patricia McManus Edward Stuart* PVH Beatrice Brooks* Jack’s Mannequin – James Wheeler Ethel Meyer* Bruce Swartz* Carrie Podles Dear Jack Foundation Becca Willcox Hon. & Mrs. J. Stephen Buis Jill Pontillo John Michaels Florence Thornhill* Scott Janssen William Mason High School Craig Clark, MD Princeton High School Robert C. Mitchell* George Vickey* Harry Jones Daniel H. Wu – Quest Diagnostics Beatrice Cuneo* Bill Kenny In loving memory June Moran* Kerry Weinberg* Michael Reina of Anita Wu Ruth Dickey* Dr. Paul Kent Maryhelen Morton* John Wilson Riders of The Storm Daniel Wyner Kiven, Kotler, Lieberman, Peggy & Margaret Dupaquier* Yahoo! Jessie Moyer* Elise Wunsch* Fox, Joffe, Goldschmidt & Steven M. Robbins Christina Evers* Kepes Team Alexa Romano Michael R. Yormark Maxine Murray Daniel Yaffe Donald Franczak Jen Klaassens Sondra Rose Mark Zafra Edward Nedved* Anonymous (4) William Knestrick Leo Frank* Security Service Federal Meredith Nicholson* Kelley LaFontaine* Credit Union John Gallo* William O’Keefe Kevin Shannahan Dr. Bruce Landon Walter Geide Dr. Hillard Lazarus Scott Shepherd Felicia O’Neal Sue Ellen Goss Melissa Ledford Silicon Valley Financial Group Mr. & Mrs. Richard Orduno Paul & Beryl Greetin* Trenton Leffingwell Skippy’s Team Karen Palmer Greg Lenners Kristie Smith Helen Halbig* Andrew & Mary Passafaro* Sam Lindenberg Stater Bros. Markets Minerva Hall* Patricia Pawson* Mindy Sterling Laurie “Lulu” and her Entourage Barbara Hanes* David E. Straseski * National Man & Woman Marion Peyton* * Deceased of the Year 25 Independent Auditors’ Report

The Board of Directors The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated statement of financial position of The Leukemia & Lymphoma Society, Inc. (LLS) as of June 30, 2011, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended. These consolidated financial statements are the responsibility of LLS’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. The prior year summarized comparative information has been derived from LLS’s 2010 consolidated financial statements and, in our report dated September 15, 2010, we expressed an unqualified opinion on those statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of LLS’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2011, and the changes in its net assets and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.

September 15, 2011 New York, New York

26 Consolidated Statement of Financial Position The Leukemia & Lymphoma Society, Inc. / June 30, 2011 (With comparative amounts at June 30, 2010) (In thousands)

2011 2010 Assets Cash and cash equivalents $ 17,866 $ 21,196 Prepaid expenses and other assets 5,171 4,707 Legacies and contributions receivable, net (note 2) 19,614 18,417 Investments (note 3) 181,876 177,489 Fixed assets, less accumulated depreciation and amortization of $8,606 and $7,965, respectively 5,413 5,132

Total assets $ 229,940 $ 226,941

Liabilities and Net Assets Liabilities: Accounts payable and accrued expenses $ 17,715 $ 16,448 Deferred revenue 17,241 16,940 Grants payable (notes 4, 5, and 6) 71,579 80,580 Total liabilities 106,535 113,968

Commitments and contingencies (notes 4, 6, and 8)

Net assets (note 9): Unrestricted 95,108 88,617 Temporarily restricted 24,405 20,668 Permanently restricted 3,892 3,688 Total net assets 123,405 112,973

Total liabilities and net assets $ 229,940 $ 226,941

See accompanying notes to consolidated financial statements.

27 Consolidated Statement of Activities The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2011 (With summarized totals for the year ended June 30, 2010) (In thousands)

Total Temporarily Permanently Unrestricted Restricted Restricted 2011 2010 Revenue Campaign contributions $ 258,976 $ 54,963 $ 105 $ 314,044 $ 279,908 Less direct donor benefit costs (38,070) – – (38,070) (36,635) Net campaign contributions 220,906 54,963 105 275,974 243,273 Legacies 1,788 5,948 – 7,736 7,054 Donated services (note 1) 5,983 – – 5,983 6,819 Net interest and dividend income (note 3) 2,311 152 – 2,463 4,430 Net increase in fair value of investments 14,396 760 127 15,283 11,335 Grant refunds 1,748 – – 1,748 1,897 Net assets released from restrictions 60,009 (59,981) (28) – – Total revenue 307,141 1,842 204 309,187 274,808

Expenses (note 10) Program Services: Research 71,985 – – 71,985 70,910 Patient and community service 109,496 – – 109,496 83,406 Public health education 44,197 – – 44,197 41,597 Professional education 7,979 – – 7,979 8,073 Total program services 233,657 – – 233,657 203,986 Supporting Services: Management and general 23,051 – – 23,051 22,462 Fund raising 42,367 – – 42,367 41,255 Total supporting services 65,418 – – 65,418 63,717 Total expenses 299,075 – – 299,075 267,703 Change in net assets before foreign currency translation adjustment and adoption of new accounting standard (note 9) 8,066 1,842 204 10,112 7,105 Foreign currency translation adjustment 320 – – 320 221 Reclassification of net assets as a result of adoption of new accounting standard (note 9) (1,895) 1,895 – – –

Change in net assets 6,491 3,737 204 10,432 7,326

Net Assets

Beginning of year 88,617 20,668 3,688 112,973 105,647 End of year $ 95,108 $ 24,405 $ 3,892 $ 123,405 $ 112,973

See accompanying notes to consolidated financial statements. 28 Consolidated Statement of Functional Expenses The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2011 (With comparative totals for the year ended June 30, 2010) (In thousands)

Program ServiceS Supporting Services Direct donor Patient and Public management Total benefit costs community health Professional and Fund Research service education education Total general raising Total 2011 2010 2011 2010 Awards and grants $ 49,906 $ – $ – $ – $ 49,906 $ – $ – $ – $ 49,906 $ 58,714 $ – $ – Therapy acceleration program (note 6) 17,895 – – – 17,895 – – – 17,895 8,227 – – Financial aid to patients – 5,579 – – 5,579 – – – 5,579 6,059 – – Co-pay assistance (note 5) – 37,947 – – 37,947 – – – 37,947 14,003 – – Donated services 1,023 4,960 – – 5,983 – – – 5,983 6,819 – – Salaries 1,525 28,549 16,968 4,072 51,114 7,512 9,146 16,658 67,772 65,650 – – Employee benefits and taxes (note 7) 239 7,938 5,265 1,241 14,683 2,170 3,278 5,448 20,131 19,425 – – Occupancy (note 8) 38 3,345 2,457 591 6,431 1,010 1,360 2,370 8,801 8,844 – – Insurance 9 240 147 25 421 51 98 149 570 579 – – Telephone 33 1,213 1,009 149 2,404 284 1,004 1,288 3,692 4,418 – – Travel 88 1,306 920 241 2,555 515 544 1,059 3,614 2,101 10,500 11,633 Printing and supplies 202 2,787 6,019 420 9,428 3,967 8,990 12,957 22,385 21,677 6,294 5,813 Equipment rentals and maintenance 22 1,014 648 149 1,833 263 413 676 2,509 1,858 – – Postage and shipping 17 1,036 3,896 136 5,085 1,861 6,376 8,237 13,322 13,022 – – Meetings 509 1,705 607 114 2,935 252 259 511 3,446 4,547 10,266 8,965 Professional fees 441 9,936 5,014 533 15,924 4,412 10,090 14,502 30,426 27,095 3,529 3,496 Miscellaneous 6 1,175 693 195 2,069 546 406 952 3,021 2,885 7,481 6,728 Depreciation and amortization 32 766 554 113 1,465 208 403 611 2,076 1,780 – – Total expenses $ 71,985 $109,496 $ 44,197 $ 7,979 $ 233,657 $ 23,051 $ 42,367 $ 65,418 $ 299,075 $267,703 $ 38,070 $ 36,635

See accompanying notes to consolidated financial statements.

Expenses Research 24.0% Program Services Patient and Community Service 36.6% Public Health Education 14.8% Professional Education 2.7% Total Program Services 78.1%

Management and General 7.7% Fundraising 14.2% supporting Services Total Supporting Services 21.9%

Total Expenses 100.0%

29 Consolidated Statement of cash flows The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2011 (With comparative amounts for the year ended June 30, 2010) (In thousands)

2011 2010 Cash flows from operating activities: Change in net assets $ 10,432 $ 7,326

Adjustments to reconcile change in net assets to net cash used in operating activities:

Net increase in fair value of investments (15,283) (11,335) Permanently restricted revenue collected (105) (84) Depreciation and amortization 2,076 1,780 (Decrease) increase in allowance for uncollectible accounts (426) 415

Changes in operating assets and liabilities:

Prepaid expenses and other assets (464) (318) Legacies and contributions receivable (771) 3,920 Accounts payable and accrued expenses 1,267 1,766 Deferred revenue 301 1,461 Grants payable (9,001) (5,188)

Net cash used in operating activities (11,974) (257)

Cash flows from investing activities: Purchases of fixed assets (2,357) (2,296) Purchases of investments (49,023) (119,968) Sales of investments 59,919 115,437

Net cash provided by (used in) investing activities 8,539 (6,827)

Cash flows from financing activities:

Permanently restricted contributions collected 105 84

Net cash provided by financing activities 105 84

Net decrease in cash and cash equivalents (3,330) (7,000) Cash and cash equivalents at beginning of year 21,196 28,196

Cash and cash equivalents at end of year $ 17,866 $ 21,196

See accompanying notes to consolidated financial statements.

30 Notes to Consolidated Financial Statements The Leukemia & Lymphoma Society, Inc. / June 30, 2011 (with comparative amounts as of and for the year ended June 30, 2010)

1. Organization and Significant Accounting Policies Subsequent Events LLS evaluated subsequent events after the statement of financial position date of June 30, 2011 through Organization September 15, 2011, which was the date the consolidated financial statements were issued, and concluded The Leukemia & Lymphoma Society, Inc. (LLS) is an international not-for-profit health agency that no additional disclosures are required. dedicated to seeking the cause and cure of leukemia, lymphoma, Hodgkin’s disease, and myeloma and improving the quality of life of patients and their families. LLS’s principal activities include: awarding Net Asset Classifications research grants; facilitating psychosocial support groups; providing financial aid to patients; answering To ensure observance of limitations and restrictions placed on the use of resources available to LLS, phone requests for blood cancer information made to LLS’s Information Resource Center; funds that have similar characteristics have been classified into three net asset categories as follows: and disseminating educational information about blood cancers in the form of publications, internet Unrestricted net assets: Consist of funds that are fully available, at the discretion of LLS’s Board sites, conference calls, and symposia sponsorship for both the medical community and the general public. of Directors, for LLS to utilize in any of its programs or supporting services. Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time Tax-Exempt Status period or purpose. LLS qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) Permanently restricted net assets: Consist of funds that contain donor-imposed restrictions requiring and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). that the principal be invested in perpetuity and that only the income be used. Income earned on these Additionally, since LLS is publicly supported, contributions to LLS qualify for the maximum charitable funds are recorded as temporarily restricted net assets and are released from restriction when the contribution deduction under the Internal Revenue Code. donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) is registered as a charitable organization with the Board-approved spending policy (note 9). under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement Foreign Currency Translation requirements are met. LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency impact Principles of Consolidation of the translation of the financial statements of LLSC to U.S. dollars is included as a translation The accompanying consolidated financial statements include the accounts of LLS, which encompasses the adjustment in the consolidated statement of activities. Home Office of LLS and its fifty-five chapters in the United States, LLSC and its four chapters Fair Value Measurements in Canada, and LLS’s not-for-profit affiliates, The Leukemia & Lymphoma Society Research Programs, Fair value is defined as the exchange price that would be received for an asset or paid to transfer Inc. and The Leukemia & Lymphoma Society Research Foundation. All significant intercompany a liability (an exit price) in the principal or most advantageous market for the asset or liability and intra-LLS accounts and transactions have been eliminated in consolidation. in an orderly transaction between market participants at the measurement date. The three levels Estimates of the fair value hierarchy are as follows: The preparation of the consolidated financial statements in conformity with generally accepted Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities accounting principles requires LLS’s management to make estimates and assumptions that affect that a reporting entity has the ability to access at the measurement date. the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the fair value Level 2 inputs other than quoted prices included within Level 1 that are observable of alternative investments, the allowance for uncollectible accounts, and the allocation of expenses. Actual for the asset or liability, either directly or indirectly. results could differ from those estimates. Level 3 unobservable inputs for the asset or liability.

Risks and Uncertainties LLS follows the provisions of Accounting Standards Codification (ASC) 820,Fair Value Measurements LLS invests in various investment securities. Investment securities are exposed to various risks and Disclosures (ASC 820), for certain alternative investments that do not have readily determinable such as interest rate, fluctuations in market security values, and credit risks. Due to the level of risk fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, associated with certain investment securities, it is at least reasonably possible that changes in the values as a practical expedient, for the estimation of the fair value of investments in investment companies of investment securities will occur in the near term and that such changes could materially affect for which the investment does not have a readily determinable fair value, using net asset value per share the amounts reported in the statement of financial position. or its equivalent, as reported by the investment managers.

Summarized Financial Information Most investments classified in Levels 2 and 3 consist of shares or units in investment funds as opposed The consolidated financial statements are presented with 2010 summarized or comparative information. to direct interests in the funds’ underlying holdings, which may be marketable. Because the net asset With respect to the consolidated statement of activities, such prior year information is not presented value reported by each fund is used as a practical expedient to estimate the fair value of LLS’s interest by net asset class and, in the consolidated statement of functional expenses, 2010 expenses by object therein, its classification in Level 2 or 3 is based on LLS’s ability to redeem its interest at or near June 30. are presented in total rather than by functional category. Accordingly, such information should be If the interest can be redeemed in the near term, the investment is classified as Level 2. The classification read in conjunction with LLS’s 2010 consolidated financial statements from which the summarized of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree information was derived. of difficulty in estimating the fair value of each investment’s underlying assets and liabilities.

31 Notes to Consolidated Financial Statements (continued) The Leukemia & Lymphoma Society, Inc. / June 30, 2011 (with comparative amounts as of and for the year ended June 30, 2010)

Contributions and Deferred Revenue 2. Legacies and Contributions Receivable Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily LLS’s legacies and contributions receivable at June 30, 2011 and 2010 consist of unconditional promises or permanently restricted revenue. When a donor restriction is met through the passage of time to give and legacies for which the underlying wills have been declared valid by the probate court and no or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted other conditions are required to be met. Amounts are scheduled to be received as follows (in thousands): net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. 2011 2010 Deferred revenue includes amounts received for special events that will be held subsequent to the fiscal Less than one year $ 17,905 $ 16,675 year-end. 1 to 5 years 2,710 3,157 After 5 years 104 232 Donated Services Subtotal 20,719 20,064 LLS has determined that certain of the donated services it receives meet the criteria for recognition Less allowance for uncollectible accounts (738) (1,164) in the consolidated financial statements. Specifically, the donated services of family support group Less discount to present value (5%) (367) (483) facilitators and research grant reviewers in the amount of $5,983,000 in 2011 and $6,819,000 in 2010 have been valued and are reported as both revenue and expense. Total $ 19,614 $ 18,417

Cash Equivalents Cash equivalents consist of short-term investments with an original maturity of three months or less Approximately, 66% and 54% of LLS’s legacies and contributions receivable are from one estate from date of purchase, except for amounts held for long-term purposes reported as investments. at June 30, 2011 and 2010, respectively. Investments Investments are stated at fair value based upon quoted market prices, except for the fair values of funds 3. Investments of hedge funds and limited partnerships, which are based on net asset values provided by the fund managers and general partners, respectively, based upon the underlying net assets of the funds The following tables present LLS’s fair value hierarchy of investments measured at fair value consistent with the concepts of ASC 820. These values are reviewed and evaluated by management. on an annual basis as of June 30, 2011 and 2010 (in thousands).

2011 Level 1 Level 2 Level 3 Fixed Assets and Depreciation Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded Money market funds and cash $ 839 $ 839 $ – $ – at cost, if purchased, or at fair value at date of donation, if contributed, and are depreciated or amortized Fixed income: using the straight-line method over the estimated useful lives of the assets or the terms of the leases, Long duration fixed income 57,910 57,910 – – if shorter. Short duration fixed income 42,826 42,826 – – Income Taxes Other 1,039 1,039 – – LLS recognizes the effect of income tax positions only if those tax positions are more likely than not Equities: to be sustained. Income generated from activities unrelated to LLS’s exempt purpose is subject to tax Large cap equity 16,703 16,703 – – under Internal Revenue Code Section 511. LLS did not recognize any unrelated business income tax International equity 6,552 6,552 – – liability for the years ended June 30, 2011 and 2010. Small cap equity 4,534 4,534 – – Small/mid cap equity 835 835 – – Professional Fees Professional fees included in the consolidated financial statements principally include fund-raising Alternative investments:: counsel fees, data processing services, contracted software development, and legal and auditing fees. Funds of hedge funds 35,503 – 35,503 – Limited partnership equity indices 15,135 – 15,135 – $ 181,876 $ 131,238 $ 50,638 $ –

32 The Leukemia & Lymphoma Society, Inc. / June 30, 2011 (with comparative amounts as of and for the year ended June 30, 2010)

2010 Level 1 Level 2 Level 3 The following table presents a reconciliation for all Level 3 assets measured at fair value Money market funds and cash $ 537 $ 537 $ – $ – as of June 30, 2011 and 2010 (in thousands).

Fixed income: Level 3 Assets

Long duration fixed income 53,153 53,153 – – 2011 2010 Short duration fixed income 41,787 41,787 – – Balance at July 1 $ 15,992 $ 16,303 Other 3,498 – 3,498 – Purchases – 15,750 Equities: Investment expense (211) (131) Large cap equity 14,149 14,149 – – Net increase in fair value 1,118 286 All cap equity 5,572 5,572 – – Transfers to Level 2 (16,899) (16,216) International equity 3,521 3,283 238 – Balance at June 30 $ – $ 15,992 Small cap equity 8,175 8,175 – – Small/mid cap equity 641 – 641 – Alternative investments: 4. Awards and Grants Funds of hedge funds 35,004 – 19,462 15,542 Limited partnership equity indices 11,452 – 11,002 450 Awards and grants for research are recognized as expense in the year approved by LLS’s Board of $ 177,489 $ 126,656 $ 34,841 $ 15,992 Directors. Multiyear grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. In addition to unconditional grants payable of $66,098,000 at June 30, 2011, LLS has grant commitments of $63,500,000 that Investment expenses of $752,000 and $580,000 have been netted against interest and dividend income are conditioned upon future events and, accordingly, are not recorded. for the years ended June 30, 2011 and 2010, respectively. The unrealized gains and losses were $7,428,000 and $10,344,000 for the years ended June 30, 2011 and 2010, respectively. 5. Co-Pay Assistance Program LLS invests in certain alternative investments, through “funds of hedge funds” investments, which invest in multiple strategies through a portfolio of hedge fund managers to provide diversification and reduce The Co-Pay Assistance program offers assistance to patients in meeting their insurance co-pay manager risk. These strategies create indirect exposure to LLS through short sales of securities, trading obligations for prescription medications or private/public health insurance premiums. Amounts awarded in future and forward contracts, and other derivative products. Derivatives are investment contracts used under the program are expensed in the year approved based on the available funding in the program. to hedge risk. While these financial instruments may contain varying degrees of risk, LLS’s risk with Approximately $3,931,000 and $4,374,000 were included in the grants payable balances for amounts respect to such transactions is limited to its capital balance in each investment. awarded but unpaid at June 30, 2011 and 2010, respectively.

The underlying holdings of the limited partnership equity indices are principally domestic and 6. Therapy Acceleration Program (TAP) international marketable securities. TAP is LLS’s strategic initiative to speed the development of blood-cancer treatments and supportive LLS’s alternative investments contain various redemption restrictions with required written notice diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP ranging from 70 to 95 days. As of June 30, 2011, the following table summarizes the composition provides funding for investigational new drug-enabling studies and clinical-stage projects. TAP contracts of such investments at fair value by the various redemption provisions (in thousands): are recognized as an expense in the year program milestones are achieved. Approximately $1,550,000 and $1,375,000 were included in the grants payable balances for milestones achieved but unpaid Redemption Period Amount at June 30, 2011 and 2010, respectively. Multiyear contracts, which are generally two to three years Monthly $ 17,901 in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion Quarterly 32,737 of LLS’s Board of Directors. LLS has contract commitments of $25,169,000 at June 30, 2011 that Total $ 50,638 are conditioned upon future events and, accordingly, are not recorded.

As of June 30, 2011 and 2010, LLS has no unfunded commitments on its alternative investments. 7. Pension Plan

LLS has a defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee’s salary and years of service. Expenses under this plan aggregated $3,823,000 and $4,072,000 for the years ended June 30, 2011 and 2010, respectively.

33 Notes to Consolidated Financial Statements (continued) The Leukemia & Lymphoma Society, Inc. / June 30, 2011 (with comparative amounts as of and for the year ended June 30, 2010)

LLS has a 457(b) deferred compensation plan (the 457 Plan), for its executive staff. The 457 Plan Accounting guidance associated with the enactment of NYPMIFA as set forth in Accounting Standards is a nonqualified deferred compensation plan subject to the provisions of the Internal Revenue Code Codification (ASC) No. 958-205,Not-for-Profit Entities, requires the portion of the donor restricted Section 457. Expenses under the 457 Plan approximated $167,000 and $120,000 for the years ended endowment fund that is not classified as permanently restricted to be classified as temporarily restricted June 30, 2011 and 2010, respectively. The assets and liabilities of the 457 Plan are included in investments net assets until appropriated for expenditure in a manner consistent with the standard of prudence and accounts payable in the accompanying consolidated statement of financial position and amounted prescribed by NYPMIFA. The adoption of the ASC’s guidance resulted in a $1,895,000 reclassification to approximately $973,000 and $546,000 at June 30, 2011 and 2010, respectively. from unrestricted to temporarily restricted net assets in 2011. The following table presents changes in the donor-restricted endowment funds for the year ended 8. Lease Commitments June 30, 2011 (in thousands). Temporarily Permanently The leases for premises, which LLS’s Home Office and chapters occupy, expire on various dates through Unrestricted restricted restricted Total August 31, 2018 and provide for certain payments subject to escalation and periodic rate increases relating Endowment net assets at July 1 $ 1,895 $ 362 $ 3,688 $ 5,945 to real estate taxes, operating expenses, and utilities. The Home Office lease expires in March 2016. Investment income – 152 – 152 Net appreciation – 760 127 887 The approximate minimum aggregate future annual rental commitments are summarized as follows Contributions – 111 105 216 (in thousands): Net assets released – – (28) (28) Reclassification upon adoption of ASC 958-205 (1,895) 1,895 – – Year ending June 30: 2012 $ 7,864 Endowment net assets at June 30 $ – $ 3,280 $ 3,892 $ 7,172 2013 6,242 2014 5,285 2015 4,771 The following table presents changes in the donor-restricted endowment funds for the year ended 2016 3,098 June 30, 2010 (in thousands). Thereafter 909 Temporarily Permanently Unrestricted restricted restricted Total Total $ 28,169 Endowment net assets at July 1 $ 1,396 $ 397 $ 3,500 $ 5,293 Investment (expense) income (74) 65 104 95 9. Temporarily and Permanently Restricted Net Assets Net appreciation 473 – – 473 Contributions – – 84 84 Temporarily restricted net assets and the income earned on permanently restricted net assets Net assets released 100 (100) – – are available for the following purposes at June 30, 2011 and 2010 (in thousands): Endowment net ass ets at June 30 $ 1,895 $ 362 $ 3,688 $ 5,945

2011 2010 Temporarily Permanently Temporarily Permanently 10. Joint Costs Allocation Restricted Restricted Restricted Restricted Time restrictions $ 15,259 $ – $ 12,344 $ – For the years ended June 30, 2011 and 2010, LLS incurred joint costs for informational materials Research 5,450 3,016 3,983 3,123 and activities that included fund raising appeals as follows (in thousands): Patient service 3,608 730 4,180 516 2011 2010 Other 88 146 161 49 Fund raising $ 12,543 $ 12,114 Total $ 24,405 $ 3,892 $ 20,668 $ 3,688 Patient and community service 1,078 1,049 Public health education 10,725 10,537 In September 2010, New York State enacted the New York Prudent Management of Institutional Funds Total $ 24,346 $ 23,700

Act (NYPMIFA), which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument. LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS’s overall investment strategy.

34 NAtional Leaders

Chair Board of Directors James H. Davis, PhD, JD Armand Keating, MD Norbert J. Sieber Human Genome Sciences, Inc. Princess Margaret Hospital NJS Consultants Scott Carroll James A. Beck Rockville, MD Toronto, Ontario, Canada Miami, FL Jackson Lewis Hefren-Tillotson, Inc. Cincinnati, OH Butler, PA Thomas L. Fitzpatrick Joseph B. Kelley Jay L. Silver Saint Gobain Corporation Lilly USA, LLC Sugar Land, TX Vice Chair Jorge L. Benitez Worcester, MA Washington, DC Timothy Durst Accenture William M. Ward, Jr. Baker Botts LLP Coral Gables, FL D. Gary Gilliland, MD, PhD Rodman N. Myers Presbyterian Manors of Mid-America Dallas, TX Merck & Co., Inc. Honigman Miller Schwartz Wichita, KS Elizabeth Clark, PhD, MPH, North Wales, PA and Cohn ACSW Secretary/Treasurer Detroit, MI Louise Warner National Association Steven L. Hooker Chagrin Falls, OH Kevin R. Ryan of Social Workers Citrin Cooperman & Company, LLP Portland, OR Derek M. Raghavan, Washington, DC Matthew E. Winter Philadelphia, PA MD, PhD, FACP Raanan Horowitz Carolinas HealthCare System Allstate Financial Jorge Cortes, MD Elbit Systems of America, LLC Charlotte, NC Northbrook, IL 60062 The University of Texas Fort Worth, TX M.D. Anderson Cancer Center Kenneth M. Schwartz Michele Wong Houston, TX John M. Kamins Ernst & Young, LLP Synergex International Corporation Foster, Swift, Collins & Smith, PC New York, NY Gold River, CA Farmington Hills, MI

Senior Staff

President & Chief Information Officer Senior Vice President The Leukemia & Lymphoma Chief Executive Officer Field Development Jeff Como Society of Canada John E. Walter George Omiros President Senior Vice President Canadian Operations Chief Mission Officer Public Policy Senior Vice President Nancy Allen Research & Scientific Revenue Generation George Dahlman Programs Michael Osso Louis J. DeGennaro, PhD Senior Vice President Patient Services Senior Vice President Chief Marketing Volunteer Engagement Hildy Dillon & Revenue Officer David Timko Nancy L. Klein Senior Vice President Human Resources Senior Vice President Chief Financial Officer Research Philip Kozlowski Jimmy Nangle Richard C. Winneker, PhD

35 Offices

Alabama Florida Louisiana New Mexico Pennsylvania Washington D.C.

100 Chase Park South n Suite 220 2 Oakwood Boulevard n Suite 200 3636 South 1-10 Service Road 4600-A Montgomery Boulevard NE 555 North Lane n Suite 5010 5845 Richmond Highway n Suite 800 Birmingham, AL 35244 Hollywood, FL 33020 Suite 304 Suite 201 Conshohocken, PA 19428 Alexandria, VA 22303 205.989.0098 954.744.5300 Metairie, LA 70001 Albuquerque, NM 87109 610.238.0360 703.399.2900 504.837.0945 505.872.0141 Alaska 3319 Maguire Boulevard n Suite 101 800 Corporate Circle n Suite 100 West Virginia See Washington State Orlando, FL 32803 Maine New York Harrisburg, PA 17110 See Pittsburgh, PA 407.898.0733 See Massachusetts 5 Computer Drive West n Suite 100 717.652.6520 Arizona Wisconsin 4360 Northlake Boulevard n Suite 109 Albany, NY 12205 333 East Carson Street n Suite 441 3877 North 7th Street n Suite 300 Palm Beach Gardens, FL 33410 Maryland 518.438.3583 Pittsburgh, PA 15219 200 South Executive Drive n Suite 203 Phoenix, AZ 85014 100 Painters Mill Road n Suite 800 Brookfield, WI 53005 561.775.9954 n 412.395.2873 602.567.7600 Owings Mills, MD 21117 4053 Maple Road Suite 110 262.790.4701

n Amherst, NY 14226 3507 East Frontage Road Suite 300 443.471.1600 Rhode Island 716.834.2578 Arkansas Tampa, FL 33607 1210 Pontiac Avenue Wyoming Massachusetts See Missouri 813.963.6461 1324 Motor Parkway n Suite 102 Cranston, RI 02920 See Colorado 9 Erie Drive n Suite 101 Hauppauge, NY 11749 401.943.8888 California Georgia Natick, MA 01760 631.370.7530 340 West Fallbrook Avenue 3715 Northside Parkway 508.810.1300 South Carolina Suite 101 Building 400 Northcreek n Suite 300 475 Park Avenue South n 8th Floor Puerto Rico 107 Westpark Boulevard n Suite 150 Commercial 18 Fresno, CA 93711 Atlanta, GA 30327 Michigan New York, NY 10016 Columbia, SC 29210 800 RH Todd Avenue n Suite 205 559.435.1482 404.720.7900 1471 East Twelve Mile Road 212.376.7100 803.731.4060 Building H San Juan, PR 00907 6033 West Century Boulevard 1311 Mamaroneck Avenue n Suite 130 Hawaii Madison Heights, MI 48071 South Dakota 787.725.2200 Suite 300 White Plains, NY 10605 30 Aulike Street n Suite 406 248.581.3900 See Minnesota Los Angeles, CA 90045 Kailua, HI 96734 914.949.0084 310.342.5800 808.261.3020 Minnesota North Carolina Tennessee Canada n 765 The City Drive South 8441 Wayzata Boulevard Suite 340 404 BNA Drive n Suite 102 Idaho Golden Valley, MN 55426 401 Harrison Oaks Boulevard Canada Corporate Suite 260 Suite 200 Nashville, TN 37217 n 804-2 Lansing Square Orange, CA 92868 2404 West Bank Drive Suite 103 763.852.3000 615.331.2980 Boise, ID 83705 Cary, NC 27513 Toronto, ON M2J 4P8 714.481.5600 919.367.4100 208.658.6662 Mississippi Texas 416.661.9541 x104 2143 Hurley Way n Suite 110 n 408 Fontaine Place Suite 104 8111 LBJ Freeway n Suite 425 Illinois North Dakota Atlantic Canada Region Sacramento, CA 95825 Ridgeland, MS 39157 Dallas, TX 75251 See Minnesota 1660 Hollis Street n 305 916.929.4720 651 West Washington Boulevard 601.956.7447 972.996.5900 Suite 400 Halifax, NS B3J 1V7 9150 Chesapeake Drive n Suite 100 Ohio Chicago, IL 60661 Missouri 5005 Mitchelldale n Suite 115 902.422.5999 San Diego, CA 92123 2300 Wall Street n Suite H 312.651.7350 77 West Port Plaza n Suite 480 Houston, TX 77092 BC/Yukon Region 858.277.1800 Street Louis, MO 63146-3111 Cincinnati, OH 45212 713.680.8088 Indiana 513.698.2828 1682 West 7th Avenue n Suite 310 221 Main Street n Suite 1650 314.878.0780 431 Isom Road n Suite 125 Vancouver, BC V6J 4S6 San Francisco, CA 94105 941 East 86th Street n Suite 100 23297 Commerce Park Indianapolis, IN 46240 Montana San Antonio, TX 78216 604.733.2873 415.625.1100 Cleveland, OH 44122 210.377.1775 317.726.2270 See Oregon 216.910.1200 Ontario Region 675 North First Street n Suite 1100 Utah 1502-480 University Avenue San Jose, CA 95112-5156 Iowa Nebraska 2225 City Gate Drive n Suite E 180 South 300 West n Suite 260 Toronto, ON M5G 1V2 n n Columbus, OH 43219 408.490.2666 8033 University Boulevard Suite A 10832 Old Mill Road Suite 200 416.585.2873 Des Moines, IA 50325 Omaha, NE 68154 614.476.7194 Salt Lake City, UT 84101 Colorado 515.270.6169 402.344.2242 801.519.6600 Prairies Region 720 South Colorado Boulevard Oklahoma Vermont 2020 10th Street NW Suite 500-S Kansas Nevada 500 North Broadway n Suite 250 Calgary, AB T2M 3M2 See Albany, NY Denver, CO 80246 6811 Shawnee Mission Parkway 6280 South Valley View Boulevard Oklahoma City, OK 73102 403.263.5300 720.440.8620 Cloverleaf Building #1 n Suite 202 405.953.8888 Suite 342 Virginia Shawnee Mission, KS 66202-4001 Las Vegas, NV 89118 Région de Québec 5540 Falmouth Street n Suite 101 Connecticut 913.262.1515 702.436.4220 Oregon 705-1255 University Street Richmond, VA 23230 372 Danbury Road n Suite 200 9320 SW Barbur Boulevard Montreal, QC H3B 3W1 Wilton, CT 06897 300 North Main n Suite 300 New Hampshire Suite 140 804.673.5690 514.875.1000 203.665.1400 Wichita, KS 67202 Portland, OR 97219 See Massachusetts Washington 316.266.4050 503.245.9866 Delaware New Jersey 123 36th Street n Suite 100 Kentucky Seattle, WA 98109 100 West 10th Street n Suite 209 14 Commerce Drive n Suite 301 Wilmington, DE 19801 301 East Main Street n Suite 100 Cranford, NJ 07016 206.628.0777 Louisville, KY 40202-1077 302.661.7300 908.956.6600 502.584.8490 36

The Leukemia & Lymphoma Society is a nonprofit organization that relies on the generosity of individual, foundation and corporate contributions to advance its mission.

1311 Mamaroneck Avenue Suite 310 White Plains, NY 10605 914.949.5213 www.lls.org

P001 20M 12/11